

PCT

Express Mail Mailing Label No.
 EX 688844368 US
 WORLD INTELLECTUAL PROPERTY ORGANIZATION
 International Bureau



B-27

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification 6: A61B 5/00, G01N 21/64		A1	(11) International Publication Number: WO 97/48331
			(43) International Publication Date: 24 December 1997 (24.12.97)
(21) International Application Number: PCT/US97/10729		(74) Agent: HIGHLANDER, Steven, L.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).	
(22) International Filing Date: 19 June 1997 (19.06.97)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 08/666,021 19 June 1996 (19.06.96) US			
(60) Parent Application or Grant (63) Related by Continuation US 08/666,021 (CIP) Filed on 19 June 1996 (19.06.96)			
(71) Applicant (for all designated States except US): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): RICHARDS-KORTUM, Rebecca [US/US]; 6410 Walebridge Lane, Austin, TX 78739 (US). RAMANUJAM, Nirmala [MY/US]; 224 W. Rittenhouse Square #2302, Philadelphia, PA 19103 (US). MAHADEVAN-JANSEN, Anita [IN/US]; 2207 Wicker- sham Lane #207, Austin, TX 78741 (US). MITCHELL, Michele, Follen [US/US]; Apartment 8B, 1111 Hermann, Houston, TX 77004 (US).			

Published

With international search report.

Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.

(54) Title: METHOD AND APPARATUS FOR DIAGNOSING SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX USING
FLUORESCENCE SPECTROSCOPY



(57) Abstract

The present invention involves the use of fluorescence spectroscopy in the diagnosis of cervical cancer and precancer. Using multiple illumination wavelengths, it is possible to (i) differentiate normal or inflamed tissue from squamous intraepithelial lesions (SILs) and (ii) to differentiate high grade SILs from non-high grade SILs. The detection may be performed *in vitro* or *in vivo*. Multivariate statistical analysis was employed to reduce the number of fluorescence excitation-emission wavelength pairs needed to re-develop algorithms that demonstrate a minimum decrease in classification accuracy. Fluorescence at excitation-emission wavelength pairs was used to redevelop and test screening and diagnostic algorithms that have a similar classification accuracy to those that employ fluorescence emission spectra at three excitation wavelengths. Both the full-parameter and reduced-parameter screening algorithms discriminate between SILs and non-SILs with a similar specificity and a substantially improved sensitivity relative to Pap smear screening and differentiate high grade SILs from non-high grade SILs.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

DESCRIPTION**METHOD AND APPARATUS FOR DIAGNOSING SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX USING FLUORESCENCE SPECTROSCOPY**

5

BACKGROUND OF THE INVENTION**I. Field of the Invention**

10 The invention relates to optical methods and apparatus used for the diagnosis of cervical precancers.

II. Related Art

15 There has been a significant decline in the incidence of advanced cervical cancer over the last 40 years, primarily due to the development of organized programs that target early detection of its curable precursor, cervical Squamous Intraepithelial Lesion (SIL) (SILs consist of Cervical Intraepithelial Neoplasia (CIN) and Human Papilloma Viral (HPV) infection) [1]. Even though organized screening (Pap smear) and diagnostic (colposcopy) programs are currently in place, approximately 15,900 new cases of
20 cervical cancer and 4,900 cervical cancer related deaths were reported in 1995, in the United States alone [2]. Currently, 24.5% of women with cervical cancer are under the age of 35 years, and the incidence continues to increase for women in this age group [1]. The continuing morbidity and mortality rate related to cervical cancer necessitates an improvement in the accuracy and efficacy of current detection modalities.

25

 The Pap smear is the primary screening tool for the detection of cervical cancer and its precursor [3]. In a Pap test, a large number of cells obtained by scraping the cervical epithelium are smeared onto a slide which is then fixed and stained for cytologic examination. Each smear is then examined under a microscope for the presence of

- 2 -

neoplastic cells [4]. The Pap smear's reported sensitivity and specificity range from 11-99% and 14-97%, respectively. Like many screening tests in an asymptomatic population, the Pap smear is unable to achieve a concurrently high sensitivity and high specificity [5]. The accuracy of the Pap smear is limited by both sampling and reading errors [6]. Approximately 60% of false-negative smears are attributed to insufficient sampling; the remaining 40% are due to reading errors. Because of the monotony and fatigue associated with reading Pap smears (50,000-300,000 cells per slide), the American Society of Cytology has proposed that a cyto-technologist should be limited to evaluating no more than 12,000 smears annually [7]. As a result, accurate Pap smear screening is labor intensive and requires highly trained professionals.

A patient with a Pap smear interpreted as indicating the presence of SIL is generally recommended for follow up with a diagnostic procedure called colposcopy [3]. During a colposcopic examination, the cervix is stained with acetic acid and viewed through a low power microscope to identify potential pre-cancerous sites; suspicious sites are biopsied and then histologically examined to confirm the presence, extent and severity of the SIL [8]. A patient who has high grade SIL (HG SIL) (which consists of CIN II and/or CIN III) is usually treated, whereas a patient diagnosed with low grade SIL (LG SIL) (which consists of HPV and/or CIN I) is generally followed further using colposcopy [3].

Colposcopic examination and tissue biopsy in expert hands maintains a high sensitivity (80-90%), at the expense of a significantly low specificity (50-60%) [9]. A poor specificity represents unnecessary biopsy of tissues which do not contain cervical pre-cancer. In spite of the poor specificity of this technique, extensive training is required to achieve this skill level. All biopsy specimens require histologic evaluation and, therefore, diagnosis is not immediate. The disconnection between colposcopic assessment and biopsy and definitive treatment is of particular concern in the

management of economically disadvantaged patients who may not return for treatment, particularly since cervical cancer precursors are more prevalent in groups of lower socioeconomic status [1].

5 Fluorescence spectroscopy is a technique that has the potential to improve the accuracy and efficacy of cervical pre-cancer screening and diagnosis. Fluorescence spectroscopy has the capability to quickly, non-invasively and quantitatively probe the biochemical and morphological changes that occur as tissue becomes neoplastic. The altered biochemical and morphological state of the neoplastic tissue is reflected in the
10 spectral characteristics of the measured fluorescence. This spectral information can be correlated to tissue histopathology, the current "gold standard" to develop clinically effective screening and diagnostic algorithms. These mathematical algorithms can be implemented in software, thereby enabling automated, fast, non-invasive and accurate pre-cancer screening and diagnosis in the hands of non-experts.

15 Although a complete understanding of the quantitative information contained within a tissue fluorescence spectrum has not been achieved, many groups have applied fluorescence spectroscopy for real-time, non-invasive, automated characterization of tissue pathology. Characterization of tissue pathology using auto-fluorescence [10-23] as
20 well as photosensitizer induced fluorescence [24-27] to discriminate between diseased and non-diseased human tissues *in vitro* and *in vivo* has been described in a variety of tissues.

25 Auto-fluorescence spectra of normal tissue, intraepithelial neoplasia and invasive carcinoma have been measured from several organ sites *in vivo* [13-17]. *In vivo* studies of the human colon at 370 nm excitation [13] indicated that a simple algorithm based on fluorescence intensity at two emission wavelengths can be used to differentiate normal colon and adenomatous polyps with a sensitivity and specificity of 100% and 97%,

respectively. Shomacker *et al.* [14] conducted similar studies *in vivo* at 337 nm excitation and demonstrated that a multivariate linear regression algorithm based on laser induced fluorescence spectra can be used to discriminate between normal colon and colonic polyps with a similarly high sensitivity and specificity. Lam *et al.* developed a
5 bronchoscope which illuminates tissue at 442 nm excitation and produces a false color image in near real-time which represents the ratio of fluorescence intensities at 520 nm (green) and 690 nm (red) [16,17]. *In vivo* studies demonstrated that the ratio of red to green auto-fluorescence is greater in normal bronchial tissues than in abnormal bronchial tissues [16]. In a trial with 53 patients, the sensitivity of fluorescence bronchoscopy was
10 found to be 72%, as compared to 50% for conventional white light bronchoscopy [17].

Nonetheless, a reliable diagnostic method with improved diagnostic capability for use *in vitro* and *in vivo* is needed to allow faster, more effective patient management and potentially further reduce mortality.

SUMMARY OF THE INVENTION

The present invention demonstrates that fluorescence spectroscopy can be applied, both *in vitro* and *in vivo*, to the diagnosis of cervical tissue abnormalities
20 including the clinical detection of cervical precancer.

In a first exemplary embodiment, there is provided a method of detecting tissue abnormality in a tissue sample comprising the steps of (i) providing a tissue sample; (ii) illuminating said sample with electromagnetic radiation wavelengths of about 337 nm,
25 about 380 nm and about 460 nm to produce three fluorescence intensity spectra; (iii) detecting a plurality of emission wavelengths from said fluorescence intensity spectra; and (iv) establishing from said emission wavelengths a probability that said sample is abnormal. The illumination wavelengths are advantageously in the ranges of 317-357 nm, 360-400 nm and 440-480 nm. The method may further comprise preprocessing data
30 at the emission wavelengths to reduce inter-sample and intra-sample variation. The

establishing step may comprise normalizing the spectra relative to a maximum intensity within the spectra. Optionally, the establishing step does not comprise mean-scaling the spectra.

5 Emission wavelengths may be selected at about 410 nm, about 460 nm, about 510 nm and about 580 nm for an illumination of about 337 nm; at about 460 nm, about 510 nm, about 580 nm, about 600 nm and about 640 nm for an illumination of about 380 nm; and at about 510, about 580 nm, about 600 nm, about 620 nm, about 640 nm and about 660 nm for an illumination of about 460 nm.

10

In various embodiments, the method may use illumination *in vitro* or *in vivo*. Where the method is *in vitro*, the providing step may comprise obtaining the tissue sample by biopsy. Further, the *in vitro* method may comprise generating a monolayer cell touch preparation or a pellet and ethanol fixation of the tissue sample. The
15 illumination may comprise illuminating the sample substantially normal to a surface of the sample, and wherein the detecting step comprises, detecting the spectra at an angle of approximately 20° from normal.

The method is capable of distinguishing tissues as follows: normal squamous and
20 abnormal tissue; normal columnar epithelium and abnormal tissue; inflamed and abnormal tissue; low grade SIL and high grade SIL tissue; and normal and high grade SIL tissue.

The present invention also comprises a method of developing a model for
25 differentiating normal from abnormal tissue in a tissue sample comprising the steps of (i) providing a plurality of tissue samples; (ii) illuminating the samples with electromagnetic radiation wavelengths of about 337 nm, about 380 nm and about 460 nm to produce three fluorescence intensity spectra; (iii) detecting a plurality of emission wavelengths from the fluorescence intensity spectra; (iv) forming a set of principal components from the
30 spectra, said principal components being defined as providing statistically significant differences between normal tissue and various forms of abnormal tissue; and (v)

- 6 -

subjecting said principal components to logistic discrimination to develop a relevant mathematical model. Again, the illumination wavelengths may be in the ranges of 317-357 nm, 360-400 nm and 440-480 nm.

5 In still another embodiment, there is provided a method of detecting tissue abnormality in a tissue sample comprising the steps of (i) providing a tissue sample; (ii) illuminating the sample with electromagnetic radiation wavelengths of about 337 nm, about 380 nm and about 460 nm to produce three fluorescence intensity spectra; (iii) detecting a plurality of emission wavelengths from said fluorescence intensity spectra;
10 and (iv) establishing from principal components PC1, PC3 and PC7 of step (iii) a probability that the sample is abnormal. Alternatively, the principal components are PC1, PC2, PC4 and PC5 or PC1, PC3 PC6 and PC8.

15 In still yet another embodiment, there is provided a method of detecting tissue abnormality in a subject *in vivo* comprising the steps of (i) illuminating a tissue sample *in vivo* with a plurality of electromagnetic radiation wavelengths to produce a plurality of fluorescence intensity spectra; (ii) detecting a plurality of emission wavelengths from the fluorescence intensity spectra; and (iii) establishing from the emission wavelengths a probability that the sample is abnormal. The illumination wavelengths advantageously
20 include at least three wavelengths having the ranges of about 317-357 nm, about 360-400 nm and about 440-480 nm. The method may further comprise the step of preprocessing data at the emission wavelengths to reduce inter-patient and intra-patient variation.

25 In still yet another embodiment, there is provided a method for diagnosing cervical precancer in a patient comprising the steps of (i) illuminating cervical tissue of the patient with a plurality of electromagnetic radiation wavelengths to produce a plurality of fluorescence intensity spectra; (ii) detecting a plurality of emission wavelengths from said fluorescence intensity spectra; (iii) comparing the plurality of
30 emission wavelengths from the patient with known emission wavelengths for normal tissue; and (iv) making a diagnostic prediction of the condition the cervical tissue.

In still yet another embodiment, the method of fluorescent spectroscopy is coupled with illuminating the sample with an electromagnetic radiation wavelength in the near infrared sufficient to produce a Raman spectrum and detecting a Raman spectrum therefrom. The near infrared illumination wavelength is about 789 nm. Advantageously, the emission frequencies are shifted about 626, 818, 978, 1070, 1175, 1246, 1330, 1454 and 1656 cm^{-1} from the illumination wavelength. In a particular embodiment, at least one of the emission frequencies is associated with compound selected from the group consisting of collagen, phospholipids and glucose-1-phosphate.

The present invention also contemplates an apparatus for detecting tissue abnormality, comprising, a light source for emitting a plurality of electromagnetic radiation wavelengths, and a probe connected to the light source, the probe being adapted to apply the plurality of radiation wavelengths to tissue under test and to gather fluorescence emitted from the tissue under test. The apparatus also, includes means, connected to probe, for detecting at least one fluorescence spectrum emitted from the tissue under test, and a programmed computer connected to the detection means, for processing the at least one fluorescence spectrum according to a predetermined algorithm to establish a probability that the tissue under test is abnormal.

The light source may comprise a nitrogen pumped laser, and the plurality of electromagnetic radiation wavelengths may be about 337 nm, about 380 nm and about 460 nm.

The apparatus may further comprise a polychromator connected between the probe and the detection means.

The probe may include emission optical fibers for applying the plurality of electromagnetic wavelengths to the tissue under test, collection optical fibers for gathering the fluorescence emitted from the tissue under test, and a shield overlying ends of the excitation optical fibers and collection optical fibers.

5 The predetermined algorithm may include principal components that predict statistically relevant differences between fluorescence emission wavelengths from normal and abnormal tissues for the plurality of applied electromagnetic radiation wavelengths.

Finally, the abnormal tissues that are predicted may include inflamed tissue, low grade SIL and high grade SIL.

10 Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

20 The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of the specific embodiments presented herein.

25 **FIG. 1.** A schematic of the portable fluorimeter used to measure cervical tissue fluorescence spectra at three excitation wavelengths.

30 **FIG. 2.** A flow chart of a formal analytical process used to develop the screening and diagnostic algorithms. The text in the dashed-line boxes represent mathematical steps implemented on the spectral data and the text in the solid line boxes represent outputs after each mathematical step (NS - normal squamous, NC - normal columnar, LG - LG SIL and HG - HG SIL).

FIGS. 3A, 3B and 3C. (FIG. 3A) Original and corresponding, (FIG. 3B) normalized and (FIG. 3C) normalized, mean-scaled spectra at 337 nm excitation from a typical patient.

5

FIGS. 4A, 4B and 4C. (FIG. 4A) Original and corresponding, (FIG. 4B) normalized and (FIG. 4C) normalized, mean-scaled spectra at 380 nm excitation from the same patient.

10

FIGS. 5A, 5B and 5C. (FIG. 5A) Original and corresponding, (FIG. 5B) normalized and (FIG. 5C) normalized, mean-scaled spectra at 460 nm excitation from the same patient.

15

FIG. 6. A plot of the posterior probability of belonging to the SIL category of all SILs and normal squamous epithelia from the calibration set. Evaluation of the misclassified SILs indicates that one samples with CIN III, two with CIN II, two with CIN I and two with HPV are incorrectly classified.

20

FIG. 7. A plot of the posterior probability of belonging to the SIL category of all SILs and normal columnar epithelia from the calibration data set. Evaluation of the misclassified SILs indicates that three samples with CIN II, three with CIN I and one with HPV are incorrectly classified.

25

FIG. 8. A plot of the posterior probability of belonging to the HG SIL category of all SILs from the calibration set. Evaluation of the misclassified HG SILs indicates that three samples with CIN III and three with CIN are incorrectly classified as LG SILs; five samples with CIN I and two with HPV are misclassified as HG SIL.

- 10 -

FIGS. 9A, 9B and 9C. Component loadings (CL) of diagnostic principal components of *constituent* algorithm (1), obtained from normalized spectra at (FIG. 9A) 337, (FIG. 9B) 380 and (FIG. 9C) 460 nm excitation, respectively.

FIGS. 10A, 10B and 10C. Component loadings (CL) of diagnostic principal components of *constituent* algorithm (2), obtained from normalized, mean-scaled spectra at (FIG. 10A) 337, (FIG. 10B) 380 and (FIG. 10C) 460 nm excitation, respectively.

FIGS. 11A, 11B and 11C. Component loadings (CL) of diagnostic principal components of *constituent* algorithm (3), obtained from normalized spectra at (A) 337, (B) 380 and (C) 460 nm excitation, respectively.

DETAILED DESCRIPTION OF THE INVENTION

I. The Present Invention

This present invention provides for the development and application of a detection technique for human cervical pre-cancer, both *in vitro* and *in vivo*, based on laser induced fluorescence spectroscopy. Fluorescence spectra from 381 cervical samples in 95 patients were acquired at three excitation wavelengths: 337, 380 and 460 nm. A general multivariate statistical algorithm is then used to analyze and extract clinically useful information from tissue spectra acquired *in vivo*. The present invention includes a screening algorithm to discriminate between SILs and-non SILs (normal squamous and columnar epithelia and inflammation); and a diagnostic algorithm to differentiate high grade SILs from non-high grade SILs (low grade SILs, normal epithelia and inflammation). The retrospective and prospective accuracy of both the screening and diagnostic algorithms is compared to the accuracy of Pap smear screening [5] and to colposcopy in expert hands [9].

- 11 -

The general multivariate statistical algorithm was developed and tested using cervical tissue spectra acquired at 337 nm excitation from 476 cervical sites in 92 patients. This algorithm could be used to differentiate SILs and normal squamous tissues with an average sensitivity and specificity of $91\% \pm 2$ and $78\% \pm 3$, respectively. Spectra of normal columnar tissues and inflammation were indistinguishable from those of SILs at this single excitation wavelength. Furthermore, a multivariate statistical algorithm based solely on spectra at 337 nm excitation only could not discriminate between high grade SILs and low grade SILs effectively.

However, multivariate statistical analysis of cervical tissue fluorescence spectra acquired *in vivo* at 380 nm and 460 nm excitation from a subset of the 92 patients indicated that spectra at these excitation wavelengths can overcome the limitations of spectra at 337 nm excitation. Spectra at 380 nm excitation from 165 sites in a first group of 40 patients could be used to differentiate SILs from normal columnar epithelia and inflammation with a sensitivity and specificity of $77\% \pm 1$ and $72\% \pm 9$, respectively; spectra at 460 nm excitation from 149 sites in a second group of 24 patients could be used to differentiate high grade SILs from low grade SILs with a sensitivity and specificity of $80\% \pm 4$ and $76\% \pm 5$, respectively.

There are two principal limitations of previous studies using fluorescence spectroscopy in the diagnosis of precancers. A first limitation is that fluorescence spectra were not acquired at all three excitation wavelengths (337, 380 and 460 nm) from every patient in the study. Therefore, analysis of spectral data from these studies did not indicate if the classification accuracy of each of the three *constituent* algorithms developed using spectra at a single excitation wavelength could be improved by utilizing tissue spectra at all three excitation wavelengths. A second limitation of these studies is that the accuracy of *composite* screening and diagnostic algorithms utilizing a combination of the *constituent* algorithms could not be evaluated since tissue spectra were not available at all three excitation wavelengths from the same group of patients.

- 12 -

In accordance with one embodiment, an algorithm based on normalized, mean-scaled spectra at 337 nm excitation can be used to differentiate between SILs and normal squamous tissues, while a second algorithm based on similarly pre-processed spectra at 380 nm excitation can be used to differentiate SILs from normal columnar tissues and samples with inflammation. A third algorithm, based on normalized tissue spectra at 460 nm excitation, can be used to discriminate between low grade SILs and high grade SILs.

Thus, a first goal of this analysis is to evaluate the accuracy of *constituent* and *composite* algorithms which address these questions. Fluorescence spectra acquired *in vivo* at all three excitation wavelengths from 381 cervical sites in 95 patients were analyzed to determine if the accuracy of each of the three *constituent* algorithms previously developed can be improved using tissue spectra at a combination of two or three excitation wavelengths rather than at a single excitation wavelength.

A second goal of this analysis is to integrate the three independently developed *constituent* algorithms which discriminate between pairs of tissue types into *composite* screening and diagnostic algorithms that can achieve discrimination between many of the clinically relevant tissue types. The effective accuracy of a *composite* screening algorithm for the identification of SILs (normal epithelium and inflammation *versus* SIL) and a *composite* diagnostic algorithm for the identification of high grade SILs (non-high grade *versus* high grade) was evaluated.

The third goal of the analysis is to determine if fluorescence intensities at a reduced number of excitation-emission wavelength pairs can be used to re-develop *constituent* and *composite* algorithms that can achieve classification with a minimum decrease in predictive ability. A significant reduction in the number of required fluorescence excitation-emission wavelength pairs could enhance the development of a cost-effective clinical fluorimeter. The accuracy of the *constituent* and *composite* algorithms based on the reduced emission variables was compared to the accuracy of those that utilize entire fluorescence emission spectra.

This ultimate result of this analysis is the clinically applicable diagnostic method for diagnosing cervical precancer in accordance with the present invention. A patient may present in the clinic with an indication of disease or for a routine check up. The decision will be made to conduct an *in vitro* or *in vivo* diagnosis. If *in vitro* is selected, a tissue sample is taken from the cervix and prepared for examination. If *in vivo* is selected, the patient is examined directly. The general steps that follow are much the same. First, the cervical tissue is illuminated with a plurality of electromagnetic radiation wavelengths to produce a plurality of fluorescence intensity spectra. Second, a plurality of emission wavelengths from the fluorescence intensity spectra is detected. Third, the plurality of emission wavelengths from the patient is compared with known emission wavelengths for normal tissue. And fourth, a diagnostic determination on the cervical tissue is made.

II. Multivariate Statistical Method Development

The five primary steps involved in multivariate statistical methods of the present invention are (i) preprocessing of spectral data from each patient to account for inter-patient variation, (ii) partitioning of the preprocessed spectral data from all patients into calibration and prediction sets, (iii) dimension reduction of the preprocessed spectra in the calibration set using principal component analysis, (iv) selection of the diagnostically most useful principal components using a two-sided unpaired t-test and (v) development of an optimal classification scheme based on logistic discrimination using the diagnostically useful principal component scores of the calibration set as inputs. These five individual steps of the multivariate statistical method are discussed below in more detail.

(i) **Preprocessing:** The objective of preprocessing is to calibrate tissue spectra for inter-patient variation which might obscure differences in the spectra of different tissue types. Four methods of preprocessing were invoked on the spectral data: (a) normalization, (b) mean scaling, (c) a combination of normalization and mean scaling and (d) median scaling.

- 14 -

Spectra were normalized by dividing the fluorescence intensity at each emission wavelength by the maximum fluorescence intensity of that sample. Normalizing a fluorescence spectrum removes absolute intensity information; methods developed from normalized fluorescence spectra rely on differences in spectral line shape information for diagnosis. If the contribution of the absolute intensity information is not significant, two advantages are realized by utilizing normalized spectra. First, it is no longer necessary to calibrate for inter-patient variation of normal tissue fluorescence intensity as in the two-stage method. And second, identification of a colposcopically normal reference site in each patient prior to spectroscopic analysis is no longer needed.

Mean scaling was performed by calculating the mean spectrum for a patient (using all spectra obtained from cervical sites in that patient) and subtracting it from each spectrum in that patient. Mean-scaling can be performed on both unnormalized (original) and normalized spectra. Mean-scaling does not require colposcopy to identify a reference normal site in each patient prior to spectroscopic analysis. However, unlike normalization, mean-scaling displays the differences in the fluorescence spectrum from a particular site with respect to the average spectrum from that patient. Therefore this method can enhance differences in fluorescence spectra between tissue categories most effectively when spectra are acquired from approximately equal numbers of non diseased and diseased sites from each patient.

Median scaling is performed by calculating the median spectrum for a patient (using all spectra obtained from cervical sites in that patient) and subtracting it from each spectrum in that patient. Like mean scaling, median scaling can be performed on both unnormalized (original) and normalized spectra, and median scaling does not require colposcopy to identify a reference normal site in each patient prior to spectroscopic analysis. However, unlike mean scaling, median scaling does not require the acquisition of spectra from equal numbers of non diseased and diseased sites from each patient.

(ii) **Calibration and Prediction Data Sets:** The preprocessed spectral data were randomly assigned into either a calibration or prediction set. The multivariate statistical method was developed and optimized using the calibration set. It was then tested prospectively on the prediction data set.

(iii) **Principal Component Analysis:** Principal component analysis (PCA) is a linear model which transforms the original variables of a fluorescence emission spectrum into a smaller set of linear combinations of the original variables called principal components that account for most of the variance of the original data set. Principal component analysis is described in Dillon W.R., Goldstein M., *Multivariate Analysis: Methods and Applications*, John Wiley and Sons, 1984, pp. 23-52, the disclosure of which is expressly incorporated herein by reference. While PCA may not provide direct insight to the morphologic and biochemical basis of tissue spectra, it provides a novel approach of condensing all the spectral information into a few manageable components, with minimal information loss. Furthermore, each principal component can be easily related to the original emission spectrum, thus providing insight into diagnostically useful emission variables.

Prior to PCA, a data matrix is created where each row of the matrix contains the preprocessed fluorescence spectrum of a sample and each column contains the pre-processed fluorescence intensity at each emission wavelength. The data matrix D (RC), consisting of R rows (corresponding to r total samples from all patients in the training set) and C columns (corresponding to intensity at c emission wavelengths) can be written as:

$$D = \begin{pmatrix} D_{11} & D_{12} & \dots & D_{1c} \\ D_{21} & D_{22} & \dots & D_{2c} \\ \vdots & \vdots & \ddots & \vdots \\ D_{r1} & D_{r2} & \dots & D_{rc} \end{pmatrix} \quad (1)$$

- 16 -

The first step in PCA is to calculate the covariance matrix, Z . First, each column of the preprocessed data matrix D is mean-scaled. The mean-scaled preprocessed data matrix, D_m is then multiplied by its transpose and each element of the resulting square matrix is divided by $(r-1)$, where r is the total number of samples. The equation for calculating Z is defined as:

$$Z = \frac{1}{r-1}(D_m / D_m) \quad (2)$$

The square covariance matrix, Z ($c \times c$) is decomposed into its respective eigenvalues and eigenvectors. Because of experimental error, the total number of eigenvalues will always equal the total number of columns (c) in the data matrix D assuming that $c < r$. The goal is to select $n < c$ eigenvalues that can describe most of the variance of the original data matrix to within experimental error. The variance, V accounted for by the first n eigenvalues can be calculated as follows:

$$V = 100 \left(\frac{\sum_{j=1}^n \lambda_j}{\sum_{j=1}^c \lambda_j} \right) \quad (3)$$

The criterion used in this analysis was to retain the first n eigenvalues and corresponding eigenvectors that account for 99 % of the variance in the original data set.

Next, the principal component score matrix can be calculated according to the following equation:

$$R = DC \quad (4)$$

where, D (RC) is the preprocessed data matrix and C ($c \times n$) is a matrix whose columns contain the n eigenvectors which correspond to the first n eigenvalues. Each row of the score matrix R ($r \times c$) corresponds to the principal component

- 17 -

scores of a sample and each column corresponds to a principal component. The principal components are mutually orthogonal to each other.

Finally, the component loading is calculated for each principal component. The component loading represents the correlation between the principal component and the variables of the original fluorescence emission spectrum. The component loading can be calculated as shown below:

$$CL_{ij} = \frac{C_{ij}}{\sqrt{S_{ii}}} \sqrt{\lambda_j} \quad (5)$$

where, CL_{ij} represents the correlation between the i th variable (preprocessed intensity at i th emission wavelength) and the j th principal component. C_{ij} is the i th component of the j th eigenvector, λ_j is the j th eigenvalue and S_{ii} is the variance of the i th variable.

Principal component analysis was performed on each type of preprocessed data matrix, described above. Eigenvalues accounting for 99% of the variance in the original preprocessed data set were retained. The corresponding eigenvectors were then multiplied by the original data matrix to obtain the principal component score matrix R .

(iv) *Student's T-Test*: Average values of principal component scores were calculated for each histo-pathologic tissue category for each principal component obtained from the preprocessed data matrix. A two-sided unpaired student's t -test was employed to determine the diagnostic contribution of each principal component. Such a test is disclosed in Devore J.L., *Probability and Statistics for Engineering and the Sciences*, Brooks/Cole, 1992, and in Walpole R.E., Myers R.H., *Probability and Statistics for Engineers and Scientists*, Macmillan Publishing Co., 1978, Chapter 7, the disclosures of which are expressly incorporated herein by reference. The hypothesis that the means of the principal

- 18 -

component scores of two tissue categories are different were tested for 1) normal squamous epithelia and SILs, 2) columnar normal epithelia and SILs and 3) inflammation and SILs. The t-test was extended a step further to determine if there are any statistically significant differences between the means of the principal component scores of high grade SILs and low grade SILs. Principal components for which the hypothesis stated above were true below the 0.05 level of significance were retained for further analysis.

(v) *Logistic Discrimination*: Logistic discriminant analysis is a statistical technique that can be used to develop diagnostic methods based on posterior probabilities, overcoming the drawback of the binary decision scheme employed in the two-stage method. This statistical classification method is based on Bayes theorem and can be used to calculate the posterior probability that an unknown sample belongs to each of the possible tissue categories identified. Logistic discrimination is discussed in Albert A. Harris E.K., *Multivariate Interpretation of Clinical Laboratory Data*, Marcel Dekker, 1987, the disclosure of which is expressly incorporated herein by reference. Classifying the unknown sample into the tissue category for which its posterior probability is highest results in a classification scheme that minimizes the rate of misclassification.

For two diagnostic categories, G_1 and G_2 , the posterior probability of being a member of G_1 , given measurement x , according to Bayes theorem is:

$$P(G_1|X) = \frac{P(x|G_1)P(G_1)C(2|1)}{P(x|G_1)P(G_1)C(2|1) + P(x|G_2)P(G_2)C(1|2)} \quad (6)$$

where $P(x \in G_i)$ is the conditional joint probability that a tissue sample of type i will have principal component score x , and $P(G_i)$ is the prior probability of finding tissue type i in the sample population. $C(j \neq i)$ is the cost of misclassifying a sample into group j when the actual membership is group i .

- 19 -

The prior probability $P(G_i)$ is an estimate of the likelihood that a sample of type i belongs to a particular group when no information about it is available. If the sample is considered representative of the population, the observed proportions of cases in each group can serve as estimates of the prior probabilities. In a clinical setting, either historical incidence figures appropriate for the patient population can be used to generate prior probabilities, or the practitioner's colposcopic assessment of the likelihood of precancer can be used to estimate prior probabilities.

The conditional probabilities can be developed from the probability distributions of the n principal component scores for each tissue type, i . The probability distributions can be modeled using the gamma function, which is characterized by two parameters, alpha and beta, which are related to the mean and standard deviation of the data set. The Gamma function is typically used to model skewed distributions and is defined below:

$$f(x; \alpha, \beta) = \frac{1}{\beta^\alpha \Gamma(\alpha)} x^{\alpha-1} e^{-x/\beta} \quad (7)$$

The gamma function can be used to calculate the conditional probability that a sample from tissue type i , will exhibit the principal component score, x . If more than one principal component is needed to describe a sample population, then the conditional joint probability is simply the product of the conditional probabilities of each principal component (assuming that each principal component is an independent variable) for that sample population.

III. Instrumentation

Fluorescence occurs when a fraction of the light absorbed by the tissue is reradiated at emission wavelengths that are longer than the excitation light. Thus, the apparatus of the present invention includes a controllable illumination device for emitting a plurality of electromagnetic radiation wavelengths selected to cause a tissue to produce

- 20 -

a fluorescence intensity spectrum. Typically, the light source is a laser. Also included are an optical system for applying the plurality of radiation wavelengths to a tissue sample, a fluorescence intensity spectrum detecting device for detecting an intensity of fluorescence spectra emitted by the sample as a result of illumination by the plurality of electromagnetic radiation wavelengths. Optionally, the system may include a data processor, connected to the detecting device, for analyzing detected fluorescence spectra to calculate a probability that the sample is abnormal.

A schematic of the portable fluorimeter which was used to acquire cervical tissue fluorescence spectra at three excitation wavelengths is shown in FIG. 1 (1). The fiber-optic probe includes a central fiber surrounded by a circular array of six fibers; all seven fibers have the same characteristics (0.22 NA, 200 μm core diameter). Three fibers along the diameter of the distal end of the probe (FIG. 1 (3)) are used for excitation light delivery (overlap of the illumination area viewed by the three excitation fibers is greater than 85%). The purpose of the remaining four fibers is to collect the emitted fluorescence from the area (1 mm diameter) directly illuminated by the probe. A quartz shield at the tip of the distal end of the probe which is in direct tissue contact (FIG. 1 (5)) provides a fixed distance between the optical fibers and the tissue surface so fluorescence intensity can be measured in calibrated units.

Two nitrogen pumped-dye lasers are used to provide illumination at three different excitation wavelengths: one laser serves to deliver excitation light at 337 nm (fundamental) and has a dye module which is used to generate light at 380 nm using the fluorescent dye, BBQ (1E-03 M in 7 parts toluene and 3 parts ethanol). The dye module of the second laser is used to provide illumination at 460 nm, using the fluorescent dye, Coumarin 460 (1E-02 M in ethanol). Laser illumination at each excitation wavelength, 337, 380 and 460 nm is coupled into each of the excitation fibers. In this study, the average transmitted pulse energies at 337, 380 and 460 nm excitation were 12, 9 and 14 μJ , respectively. The laser characteristics were a 5 ns pulse duration and a repetition rate of 30 Hz.

The proximal ends of the four emission collection fibers are arranged in a circular array and imaged at the entrance slit of a polychromator coupled to a 1,024 intensified diode array controlled by a multi-channel analyzer. 360, 400 and 470 nm long pass filters are used to block scattered excitation light at 337, 380 and 460 nm excitation, respectively from the detector. A 205 ns collection gate, synchronized to the leading edge of the laser pulse using a pulser (Princeton Instruments, PG200), eliminates the effects of the colposcope's white light illumination during fluorescence measurements. Data acquisition is computer controlled.

IV. Combining Fluorescence and Raman Spectroscopies

The present invention also contemplates a method that combines fluorescence spectroscopy, as described above, with NIR Raman spectra, *in vitro* or *in vivo*. This is accomplished through a light source, sequentially or simultaneously, in conjunction with an optical coupling system for the application and analysis of both kinds of data. For example, a probe is selectively coupled to ultraviolet or visible sources of electromagnetic radiation to excite fluorescence, and then selectively coupled to NIR sources to excite fluorescence-free Raman spectra. The fluorescence spectra may be used to improve the analytical rejection of fluorescence from the Raman spectrum.

In one embodiment, the apparatus comprises a diachronic mirror or swing-way mirror so that each electromagnetic radiation source is selectively coupled to the optical excitation fiber(s). Similarly, light collected by the collection fiber may be selectively coupled to the appropriate detectors. Alternatively, a probe may house discrete sets of fluorescence and Raman excitation and detection fibers, thereby obviating the need for mirrors.

In analyzing the spectra, fluorescence may be used advantageously to identify normal tissues and low and high grade lesions. NIR Raman spectra can be used advantageously to identify inflammation and metaplasia. Alternatively, information gathered about the tissue type, in accordance with the above-described fluorescence methods, can be used to improve the Raman diagnostic capability. This is accomplished

- 22 -

by using fluorescence spectra to calculate the posterior probability that tissue is normal, low grade or high grade SIL. Then, this classification is used as the prior probability in logistic discrimination, based on the detected Raman spectra. In yet another embodiment, information gathered with NIR Raman spectroscopy is used to calculate the posterior probability that the tissue is inflamed or metaplastic. Then, this information is used as the prior probability in logistic discrimination, based on the detected fluorescence spectrum. By the same token, Raman can improve the diagnostic performance of fluorescence by reducing misclassification of inflammation and metaplasia as precancer.

In one embodiment, the Raman method comprises illuminating a sample with an electromagnetic radiation wavelength in the near infrared to produce a Raman spectrum shifted from the illumination wavelength; detecting a plurality of emission frequencies of the spectrum; and establishing from the emission frequencies a probability that the sample is abnormal. The excitation wavelength typically is between 700 and 850 nm, with a wavelength of about 789 nm being a specific embodiment. Emission frequencies are shifted about 626, 818, 978, 1070, 1175, 1246, 1330, 1454 and 1656 cm^{-1} from 789 nm in a more specific embodiment.

Another approach that may be taken in examining Raman spectra is to look at the Raman signatures of specific compounds. In this embodiment, compounds of interest include collagen, phospholipids and glucose-1-phosphate. The Raman spectrum measured for collagen contains peaks at 770, 826, 1066, 1181, 1248, 1452 and 1660 cm^{-1} . Glucose 1-phosphate is an intermediate product in the glycogen-glucose conversion cycle and found in abundance in cervical epithelial cells. The spectrum of glucose 1-phosphate includes peaks at 850, 970, 1053, 1091, 1146 and 1350 cm^{-1} . The peaks for one major phospholipid, phosphatidylcholine, are at 740, 980, 1091, 1320 and 1454 cm^{-1} .

V. Examples

The following examples are included to demonstrate specific embodiments of the present invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors

to function well in the practice of the invention, and thus can be considered to constitute specific modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLE 1: METHODS

Clinical measurements. A randomly selected group of non-pregnant patients referred to the colposcopy clinic of the University of Texas MD Anderson Cancer Center on the basis of abnormal cervical cytology was asked to participate in the *in vivo* fluorescence spectroscopy study. Informed consent was obtained from each patient who participated and the study was reviewed and approved by the Institutional Review Boards of the University of Texas, Austin and the University of Texas, MD Anderson Cancer Center. Each patient underwent a complete history and a physical examination including a pelvic exam, a Pap smear and colposcopy of the cervix, vagina and vulva.

After colposcopic examination of the cervix, but before tissue biopsy, fluorescence spectra were acquired on average from two colposcopically abnormal sites, two colposcopically normal squamous sites and 1 normal columnar site (if colposcopically visible) from each patient. Tissue biopsies were obtained only from abnormal sites identified by colposcopy and subsequently analyzed by the probe to comply with routine patient care procedure. All tissue biopsies were fixed in formalin and submitted for histologic examination. Hemotoxylin and eosin stained sections of each biopsy specimen were evaluated by a panel of four board certified pathologists and a consensus diagnosis was established using the Bethesda classification system [1]. This classification system which has previously been used to grade cytologic specimens has now been extended to classification of histology samples. Samples were classified as normal squamous, normal columnar, inflammation, low grade SIL or high grade SIL. Samples with multiple diagnoses were classified into the most severe histo-pathologic category.

- 24 -

Prior to each patient study, the probe was disinfected and a background spectrum was acquired at all three excitation wavelengths consecutively with the probe dipped in a non-fluorescent bottle containing distilled water. The background spectrum was subtracted from all subsequently acquired spectra at corresponding excitation wavelengths for that patient. Next, with the probe placed on the face of a quartz cuvette containing a solution of Rhodamine 610 dissolved in ethylene glycol (2 mg/L), 50 fluorescence spectra were measured at each excitation wavelength. After calibration, fluorescence spectra were acquired from the cervix: 10 spectra for 10 consecutive pulses were acquired at 337 nm excitation; next, 50 spectra for 50 consecutive laser pulses were measured at 380 nm excitation and then at 460 nm excitation. The data acquisition time was 0.33 s at 337 nm excitation and 1.67 s at each 380 and 460 nm excitation per cervical site. Spectra were collected in the visible region of the electromagnetic spectrum with a resolution of 10 nm (full width at half maximum) and a signal to noise ratio of 30:1 at the fluorescence maximum at each excitation wavelength.

All spectra were corrected for the non-uniform spectral response of the detection system using correction factors obtained by recording the spectrum of an N.I.S.T traceable calibrated tungsten ribbon filament lamp. Spectra from each cervical site at each excitation wavelength were averaged and normalized to the peak fluorescence intensity of the Rhodamine 610 calibration standard at the corresponding excitation wavelength for that patient; absolute fluorescence intensities are reported in these calibrated units. In this clinical study, fluorescence spectra were acquired at all three excitation wavelengths from each cervical site from a total of 381 sites in 95 patients during colposcopy.

EXAMPLE 2: STATISTICAL METHODS

Development of screening and diagnostic algorithms: FIG. 2 illustrates a schematic of the formal analytical process used to develop screening and diagnostic algorithms for the differential detection of SILs, *in vivo*. In FIG. 2, the text in the

- 25 -

dashed-line boxes represents the mathematical steps implemented on the spectral data, and the text in the solid-line boxes represent the output after each mathematical process. There are four primary steps involved in the multivariate statistical analysis of tissue spectral data (FIG. 2). The first step is to pre-process spectral data to reduce inter-patient and intra-patient variation within a tissue type; the pre-processed spectra are then dimensionally reduced into an informative set of principal components which describe most of the variance of the original spectral data set using Principal Component Analysis (PCA). Next, the principal components which contain diagnostically relevant information are selected using an unpaired, one-sided student's t-test, and finally a classification algorithm based on logistic discrimination is developed using these diagnostically relevant principal components.

In summary, three *constituent* algorithms were developed using multivariate statistical analysis (FIG. 2): a *constituent* algorithm (1) discriminates between SILs and normal squamous tissues, a *constituent* algorithm (2) discriminates between SILs and normal columnar tissues and finally, a *constituent* algorithm (3) differentiates high grade SILs from low grade SILs. The three *constituent* algorithms were then combined to develop two *composite* algorithms (FIG. 2): *constituent* algorithms (1) and (2) were combined to develop a *composite* screening algorithm which discriminates between SILs and non SILs. All three *constituent* algorithms were then combined to develop a *composite* diagnostic algorithm which differentiates high grade SILs from non-high grade SILs.

Multivariate statistical analysis of cervical tissue spectra. As a first step, three methods of pre-processing were applied to the spectral data at each excitation wavelength: 1) normalization 2) mean-scaling and 3) a combination of normalization and mean-scaling. Similarly pre-processed spectra at each excitation wavelength were combined to create spectral inputs at the following combinations of excitation wavelengths: (337, 460) nm, (337, 380) nm, (380, 460) nm and (337, 380, 460) nm. Pre-processing of spectral data resulted in four types of spectral inputs (original and three types of pre-processed spectral inputs) at four single excitation wavelengths and at four

possible combinations of multiple excitation wavelengths. Hence, there were a total of 12 spectral inputs at single excitation wavelengths and 16 spectral inputs at multiple excitation wavelengths which were evaluated using the multivariate statistical algorithm.

5 Prior to PCA, the input data matrix, D (RC) was created so each row of the matrix corresponded to the pre-processed fluorescence spectrum of a sample and each column corresponded to the pre-processed fluorescence intensity at each emission wavelength. Spectral inputs at multiple excitation wavelengths were created by
10 arranging spectra at each excitation wavelength in series in the original spectral data matrix. PCA [28] was used to dimensionally reduce the pre-processed spectral data matrix into a smaller orthogonal set of linear combinations of the emission variables that account for most of the variance of the spectral data set.

15 Average values of principal component scores were calculated for each principal component of each tissue type. An unpaired, one-sided student's t-test [29] was employed to determine the diagnostic content of each principal component. The hypothesis that the means of the principal component scores of two tissue types are different was tested for (1) normal squamous epithelia and SILs, (2) normal columnar epithelia and SILs and (3) inflammation and SILs. The t-test was extended a step further
20 to determine if there were any statistically significant differences between the means of the principal component scores of high grade SILs and low grade SILs. Principal components for which the hypothesis stated above was statistically significant ($P < 0.05$) were retained for further analysis.

25 Next, a statistical classification algorithm was developed using the diagnostically useful principal components to calculate the posterior probability that an unknown sample belongs to each tissue type under consideration. The posterior probability of an unknown sample belonging to each tissue type was calculated using logistic discrimination [30]. The posterior probability is related to the prior and conditional joint
30 probabilities and to the costs of misclassification of the tissue types under consideration. The prior probability of each tissue type was determined by calculating the observed

- 27 -

proportion of cases in each group. The cost of misclassification of a particular tissue type was varied from 0 to 1 in 0.1 increments, and the optimal cost was identified when the total number of misclassified samples based on the classification algorithm was a minimum. If there was more than one cost at which the total number of misclassified samples was a minimum, the cost that maximized sensitivity was selected. The conditional joint probabilities were developed by modeling the probability distribution of each principal component of each tissue type using the normal probability density function [31], which is characterized by μ (mean) and σ (standard deviation). The best fit of the normal probability density function to the probability distribution of each principal component (score) of each tissue type was obtained in the least squares sense, using μ and σ as free parameters of the fit. The normal probability density function was then used to calculate the conditional joint probability that an unknown sample, given that it is from tissue type i , will exhibit a set of principal component scores, X .

The multivariate statistical algorithm was developed and optimized using a calibration set and then tested in an unbiased manner on a prediction set of approximately equal prior probability (Table 1). Data in the prediction set is pre-processed and organized into two prediction datasets in the following way:

Spectra obtained from each patient at each excitation wavelength are separately (1) normalized and (2) normalized, followed by mean-scaling. Spectra at each excitation wavelength, processed in a similar manner are concatenated into a vector. Two prediction data matrices are developed. In each matrix, each row is a vector containing similarly pre-processed fluorescence emission spectra at 337, 380 and 460 nm excitation concatenated and each column corresponds to pre-processed fluorescence intensity at a particular excitation emission wavelength pair.

These processed data matrices are then used to test the composite screening algorithm performance. The steps of this test are:

- 28 -

The normalized prediction data matrix (Dn') is multiplied by the reduced eigenvector matrix from normalized spectral data of the calibration set (Cn'). Cn' contains only those eigenvectors which displayed statistically significant differences for samples to be classified by constituent algorithm 1.

The posterior probabilities that a sample is SIL or normal squamous epithelium are calculated using Bayes theorem. In this calculation, the mean values and standard deviations of the PC scores for normal squamous epithelium and SILs and prior probabilities and optimal costs of misclassification of the calibration set are used.

The normalized, mean-scaled prediction data matrix (Dnm') is multiplied by the reduced eigenvector matrix from normalized, mean-scaled spectral data of the calibration set (Cnm'). Cnm' contains only those eigenvectors which displayed statistically significant differences for samples to be classified by constituent algorithm 2.

The posterior probabilities that a sample is SIL or normal columnar epithelium are calculated using Bayes theorem. In this calculation, the mean values and standard deviations of the PC scores for normal columnar epithelium and SILs and prior probabilities and optimal costs of misclassification of the calibration set are used.

Using constituent algorithm 1, samples with a posterior probability of being normal squamous epithelium greater than a threshold value are classified as non-SIL. Remaining samples are classified based on the output of constituent algorithm 2. Using constituent algorithm 2, sample with a posterior probability of being normal columnar epithelium greater than a threshold are classified as non-SIL. The remaining samples are classified as SIL.

The processed data matrices are then used to test the composite diagnostic algorithm performance. The steps of this test are:

5 The normalized prediction data matrix (D_n') is multiplied by the reduced eigenvector matrix from normalized spectral data of the calibration set (C_n'). C_n' contains only those eigenvectors which displayed statistically significant differences for samples to be classified by constituent algorithm 1.

10 The posterior probabilities that a sample is SIL or normal squamous epithelium are calculated using Bayes theorem. In this calculation, the mean values and standard deviations of the PC scores for normal squamous epithelium and SILs and prior probabilities and optimal costs of
15 misclassification of the calibration set are used.

 The normalized, mean-scaled prediction data matrix (D_{nm}') is multiplied by the reduced eigenvector matrix from normalized, mean-scaled spectral data of the calibration set (C_{nm}'). C_{nm}' contains only those eigenvectors
20 which displayed statistically significant differences for samples to be classified by constituent algorithm 2.

 The posterior probabilities that a sample is SIL or normal columnar epithelium are calculated using Bayes theorem. In this calculation, the
25 mean values and standard deviations of the PC scores for normal columnar epithelium and SILs and prior probabilities and optimal costs of misclassification of the calibration set are used.

 The normalized prediction data matrix (D_n') is multiplied by the reduced eigenvector matrix from normalized spectral data of the calibration set
30 (C_n'). C_n' contains only those eigenvectors which displayed statistically

- 30 -

significant differences for samples to be classified by constituent algorithm 3.

The posterior probabilities that a sample is HGSIL or LGSIL are calculated using Bayes theorem. In this calculation, the mean values and standard deviations of the PC scores for HGSILs and LGSILs and prior probabilities and optimal costs of misclassification of the calibration set are used.

Using constituent algorithm 1, samples with a posterior probability of being normal squamous epithelium greater than a threshold are classified as non-SIL. Remaining samples are classified based on the output of constituent algorithm 2. Using constituent algorithm 2, sample with a posterior probability of being normal columnar epithelium greater than a threshold are classified as non-SIL. Remaining samples are classified based on the output of constituent algorithm 3. Using constituent algorithm 3, samples with a posterior probability of being LGSIL greater than a threshold are classified as LGSIL. The remaining samples are classified as HGSIL.

The calibration and prediction sets were developed by randomly assigning the spectral data into the two sets with the condition that both contain roughly equal number of samples from each histo-pathologic category. The random assignment ensured that not all spectra from a single patient were contained in the same data set.

Histo-pathology	Calibration Set	Prediction Set
Normal Squamous	94	94
Normal Columnar	13	14
Inflammation	15	14
Low Grade SIL	23	24
High Grade SIL	35	35

Table 1. Histo-pathologic classification of samples from the calibration and prediction sets. Note, biopsies for histological evaluation were not obtained from colposcopically

- 31 -

normal squamous and columnar tissue sites to comply with routine patient care procedure.

Development of constituent algorithms: The multivariate statistical algorithm was developed and optimized using all 28 types of pre-processed spectral inputs from the calibration set. The algorithm was used to identify spectral inputs which provide the greatest discrimination between the following pairs of tissue types: (1) SILs and normal squamous epithelia, (2) SILs and normal columnar epithelia, (3) SILs and inflammation, and (4) high grade SILs and low grade SILs. The optimal spectral input for differentiating between two particular tissue types was identified when the total number of samples misclassified from the calibration set using the multivariate statistical algorithm was a minimum. The algorithm based on the spectral input that minimized misclassification between the two tissue types under consideration was implemented on the prediction data set.

Three multivariate statistical *constituent* algorithms were developed using tissue spectra at three excitation wavelengths. *Constituent* algorithm (1) was developed to differentiate between SILs and normal squamous epithelia; *constituent* algorithm (2) was developed to differentiate between SILs and normal columnar epithelia and *constituent* algorithm (3) could be used to discriminate between low grade SILs and high grade SILs.

Development of composite algorithms: Each of the independently developed *constituent* algorithms was intended to discriminate only between pairs of tissue types. A combination of these *constituent* algorithms was required to provide discrimination between several of the clinically relevant tissue types. Therefore, two *composite* algorithms were developed: a *composite* screening algorithm was developed to differentiate between SILs and non SILs (normal squamous and columnar epithelia and inflammation) using *constituent* algorithms (1) and (2) and a *composite* diagnostic algorithm was developed to differentiate high grade SILs from non-high grade SILs (low grade SILs, normal epithelia and inflammation) using all three *constituent* algorithms.

The *composite* screening algorithm was developed in the following manner. First, *constituent* algorithms (1) and (2) were developed independently using the calibration data set. The classification outputs from both *constituent* algorithms were used to determine if a sample being evaluated is SIL or non-SIL: first, using *constituent* algorithm (1), samples were classified as non SIL if they had a probability that is less than 0.5; otherwise, they were classified as SIL. Next, only samples that were classified as SIL based on the algorithm (1) were tested using algorithm (2). Again, samples were classified as non SIL if their posterior probability was less than 0.5; otherwise they were classified as SIL. The spectral data from the prediction set was evaluated using the *composite* screening algorithm in an identical manner.

The *composite* diagnostic algorithm was implemented in the following manner. The three *constituent* algorithms were developed independently using the calibration set. Algorithms (1) and (2) were implemented on each sample from the calibration data set, as described previously. Only samples that were classified as SIL based on algorithms (1) and (2) were tested using algorithm (3). If samples evaluated using algorithm (3) had a posterior probability greater than 0.5, they were classified as high grade SIL; otherwise they were classified as non-high grade SIL. The spectral data from the prediction set was evaluated using the *composite* diagnostic algorithm in an identical manner.

EXAMPLE 3: RESULTS

Constituent algorithms (1), (2) and (3): Table 2 summarizes the components of the optimal set of three *constituent* algorithms. *Constituent* algorithm (1) can be used to differentiate between SILs and normal squamous epithelia; algorithm (2) differentiates between SILs and normal columnar epithelia; and algorithm (3) discriminates between low grade SILs and high grade SILs.

Constituent Algorithms	Excitation Wavelengths	Pre-processing Method	PC ¹	V(%) ²	(μ, σ) ³	pp ⁴
(1) SIL vs. Normal Squamous (NS)	337, 380, 460	normalization	PC1	51	NS: (2.993, 1.589); SIL: (2.514, 0.671)	NS: 62%
			PC3	11	NS: (2.631, 0.292); SIL: (2.535, 0.427)	SIL: 38%
			PC7	3	NS: (2.850, 0.145); SIL: (2.775, 0.209)	
(2) SIL vs. Normal Columnar (NC)	337, 380, 460	normalization mean-scaling	PC1	59	NC: (2.479, 0.444); SIL: (2.737, 0.482)	NC: 28%
			PC2	12	NC: (2.894, 0.330); SIL: (2.990, 0.367)	SIL: 72%
			PC4	6	NC: (3.006, 0.186); SIL: (3.051, 0.167)	
			PC5	3	NC: (3.004, 0.101); SIL: (2.994, 0.199)	
(3) HG SIL (HG) vs. LG SIL (LG)	337, 380, 460	normalization	PC1	51	LG: (2.755, 0.663); HG (2.353, 0.759)	LG: 40%
			PC3	11	LG: (2.549, 0.394); HG (2.453, 0.497)	HG: 60%
			PC6	3	LG: (2.042, 0.180); HG (2.100, 0.180)	
			PC8	2	LG: (2.486, 0.223); HG (2.550, 0.130)	

Table 2. Components of an optimal set of three *constituent* algorithms. Algorithm (1) discriminates between SILs and normal squamous tissues, algorithm (2) discriminates between SILs and normal columnar tissues and algorithm (3) differentiates high grade (HG) SILs from low grade (LG) SILs. **Principal Component Analysis:** 1 - Principal Component; 2 - Variance accounted for by principal component. **Logistic Discrimination:** 3 - μ (mean) and σ (standard deviation) of principal component scores of tissue types under consideration; 4 - prior probabilities of tissue types under consideration.

Pre-processing: FIG. 3A illustrates average fluorescence spectra per site acquired from cervical sites at 337 nm excitation from a typical patient. All fluorescence intensities are reported in the same set of calibrated units. Corresponding normalized and normalized, mean-scaled spectra are illustrated in FIGS. 3B and 3C, respectively.

5 Evaluation of the original spectra at 337 nm excitation (FIG. 3A) indicates that the fluorescence intensity of SILs is less than that of the corresponding normal squamous tissue and greater than that of the corresponding normal columnar tissue over the entire emission spectrum. Examination of normalized spectra from this patient (FIG. 3B)

10 indicates that following normalization, the fluorescence intensity of the normal squamous tissue is greater than that of corresponding SILs over the wavelength range 360 to 450 nm only; between 460 and 600 nm, the fluorescence intensity of SILs is greater than that of the corresponding normal squamous tissue which in part reflects the longer peak emission wavelength of SILs. A comparison of the spectral line shape of SILs to that of the normal columnar tissue illustrates the opposite phenomenon. The normalized

15 fluorescence intensity of SILs is greater than that of the corresponding normal columnar tissue over the wavelength range 360 to 450 nm; however, between 460 and 600 nm, the fluorescence intensity of the normal columnar tissue is greater than that of the SILs. This spectral difference reflects the longer peak emission wavelength of the normal columnar tissue relative to that of SILs. Further evaluation of normalized spectra in FIG. 3B

20 indicates that there are spectral line shape differences between low grade SILs and high grade SILs over the wavelength range 360 to 420 nm.

The corresponding normalized, mean-scaled spectra of this patient, shown in FIG. 3C displays differences in the normalized fluorescence spectrum (FIG. 3B) from a

25 particular site with respect to the average normalized spectrum from this patient. Evaluation of FIG. 3C indicates that between 360 and 450 nm, the normalized, mean-scaled fluorescence intensity of the normal squamous tissue is greater than the mean ($Y=0$), and that of the normal columnar tissue is less than the mean. Above 460 nm, the opposite phenomenon is observed; the fluorescence intensity of the normal squamous

30 tissue is less than the mean, while that of the normal columnar tissue is greater than the mean. The fluorescence intensity of SILs lies close to the mean and is bounded by the

intensities of the two normal tissue types. In addition, between 360 and 420 nm, the normalized, mean-scaled fluorescence intensity of the low grade SIL is slightly greater than the mean, while that of the high grade SIL is less than the mean.

5 FIG. 4A illustrates average fluorescence spectra per site acquired from cervical sites at 380 nm excitation, from the same patient. FIGS. 4B and 4C show the corresponding normalized, and normalized, mean-scaled spectra, respectively. In FIG. 4A, the fluorescence intensity of SILs is less than that of the corresponding normal squamous tissue, with the low grade SIL exhibiting the weakest fluorescence intensity over the entire emission spectrum. Note that the fluorescence intensity of the normal columnar sample is indistinguishable from that of the low grade SIL. Normalized spectra at 380 nm excitation, (FIG. 4B), indicate that over the wavelength range 400 to 450 nm, the fluorescence intensity of the normal squamous tissue is slightly greater than that of SILs and that of the normal columnar tissue is less than that of SILs. The opposite phenomenon is observed above 580 nm. A careful examination of the spectra of the low grade SIL and high grade SIL indicates that between 460 and 580 nm, the normalized fluorescence intensity of the low grade SIL is higher than that of the high grade SIL. The normalized, mean-scaled spectra (FIG. 4C) enhances the previously observed normalized spectral line shape differences by displaying them relative to the average normalized spectrum of this patient. FIG. 4C indicates that between 400 to 450 nm, the fluorescence intensity of the normal squamous tissue is greater than the mean and that of the normal columnar tissue is less than the mean. The opposite phenomenon is observed above 460 nm. The fluorescence intensity of the SILs is bounded by the intensities of the two normal tissue types over the entire emission spectrum. The low grade SIL and high grade SIL also show spectral line shape differences; above 460 nm, the normalized, mean-scaled fluorescence intensity of the low grade SIL lies above the mean and that of the high grade SIL lies below the mean.

30 FIGS. 5A, 5B and 5C illustrate original, normalized and normalized, mean-scaled spectra, respectively at 460 nm excitation from the same patient. Evaluation of FIG. 5A indicates that the fluorescence intensity of SILs is less than that of the corresponding

normal squamous tissue and greater than that of the corresponding normal columnar sample over the entire emission spectrum. Evaluation of normalized spectra at this excitation wavelength (FIG. 5B) demonstrates that below 510 nm, the fluorescence intensity of SILs is less than that of the normal squamous tissue and greater than that of the corresponding normal columnar tissue. Above, 580 nm, the normalized fluorescence intensity of SILs is less than that of the normal columnar tissue and greater than that of normal squamous tissue. Note that there are spectral line shape differences between the low grade SIL and high grade SIL between 580 and 660 nm; the normalized fluorescence intensity of the low grade SIL is greater than that of the high grade SIL. The normalized, mean-scaled spectra shown in FIG. 5C reflects the differences observed in the normalized spectra relative to the average normalized spectrum of this patient. Below 510 nm, the fluorescence intensity of the normal squamous tissue is greater than the mean, while that of the normal columnar tissue is less than the mean. Above 580 nm, the opposite phenomenon is observed. The fluorescence intensity of the SILs lies between those of the two normal tissue types. Above 580 nm, the fluorescence intensity of the low grade SIL is greater than the mean and that of the high grade SIL is less than the mean.

Principal Component Analysis and Logistic Discrimination: Constituent algorithm (1) which differentiates SILs from normal squamous tissues. A constituent algorithm based on normalized spectra arranged in series at all three excitation wavelengths provided the greatest discrimination between SILs and normal squamous tissues. The algorithm demonstrated an incremental improvement in sensitivity without sacrificing specificity relative to the previously developed constituent algorithm (1) that employed normalized, mean-scaled spectra at 337 nm excitation only. Multivariate statistical analysis of normalized tissue spectra at all three excitation wavelengths, indicated three principal components show statistically significant differences between SILs and normal squamous tissues (Table 2). These three principal components account collectively for 65% of the total variance of the spectral data set. Logistic discrimination was used to develop a classification algorithm to discriminate between SILs and normal squamous epithelia based on these three informative principal components. Prior

- 37 -

probabilities were determined by calculating the percentage of each tissue type from the data set: 62% normal squamous tissues and 38% SILs. The cost of misclassification of SIL was optimized at 0.7. Posterior probabilities of belonging to each tissue type were calculated for all samples from the data set, using the known prior probabilities, cost of misclassification of SILs and the conditional joint probabilities calculated from the normal probability density function. FIG. 6 illustrates the retrospective accuracy of the algorithm applied to the calibration data set. The posterior probability of being classified into the SIL category is plotted for all SILs and normal squamous epithelia. FIG. 6 indicates that 92% of high grade SILs and 83% of low grade SILs are correctly classified with a posterior probability greater than 0.5. Approximately 70% of colposcopically normal squamous epithelia are correctly classified with a posterior probability less than 0.5.

The confusion matrix in Table 3 compares the retrospective accuracy of the algorithm on the calibration data set to its prospective accuracy on the prediction set. In the confusion matrix, the first row corresponds to the histo-pathologic classification and the first column corresponds to the spectroscopic classification of the samples. A prospective evaluation of the algorithm's accuracy indicates that there is a small increase in the proportion of correctly classified low grade SILs and no change in the proportion of correctly classified low grade SILs or normal squamous tissues. Note that the majority of normal columnar tissues and samples with inflammation from both calibration and prediction sets are misclassified as SIL using this algorithm. Evaluation of the misclassified SILs from the calibration set indicates that one sample with CIN III, two with CIN II, two with CIN I and two with HPV are incorrectly classified. From the prediction set, two samples with CIN III, one with CIN II, two with CIN I and one with HPV are incorrectly classified as non-SIL.

Classification in Calibration Set	Normal Squamous	Normal Columnar	Inflammation	LG SIL	HG SIL
Non SIL	68%	8%	7%	17%	9%
SIL	32%	92%	93%	83%	91%
Classification in Prediction Set	Normal Squamous	Normal Columnar	Inflammation	LG SIL	HG SIL
Non SIL	68%	29%	21%	12%	9%
SIL	32%	71%	79%	88%	91%

Table 3. Accuracy of *constituent* algorithm (1) which differentiates SILs and normal squamous tissues from the calibration and prediction sets. The first column corresponds to the spectroscopic classification and the first row corresponds to the histo-pathologic classification.

Constituent algorithm (2) which differentiates SILs from normal columnar tissues. The greatest discrimination between SILs and normal columnar epithelia was achieved using a *constituent* algorithm based on normalized, mean-scaled spectra at all three excitation wavelengths. This algorithm demonstrated a substantially improved sensitivity for a similar specificity relative to the previously developed *constituent* algorithm (2) which used normalized, mean-scaled spectra at 380 nm excitation, only. Multivariate statistical analysis of a combination of normalized, mean-scaled tissue spectra at all three excitation wavelengths resulted in four principal components that demonstrate statistically significant differences between SILs and normal columnar epithelia (Table 2). These four principal components collectively account for 80% of the total variance of the spectral data set. Logistic discrimination was employed to develop a classification algorithm to discriminate between SILs and normal columnar epithelia. The prior probabilities were determined to be: 28% normal columnar tissues and 72% SILs. The optimized cost of misclassification of SIL was equal to 0.58. Posterior probabilities of belonging to each tissue type were calculated for all samples from the data set. FIG. 7 illustrates the retrospective accuracy of the algorithm applied to the calibration data set. The posterior probability of being classified into the SIL category is plotted for all SILs and normal columnar samples examined. FIG. 7 graphically

indicates that 91% of high grade SILs and 83% of low grade SILs have a posterior probability that is greater than 0.5. 76% of colposcopically normal columnar epithelia are correctly classified with a posterior probability less than 0.5.

5 The confusion matrix in Table 4 compares the retrospective accuracy of the *constituent* algorithm on the calibration data set to its prospective accuracy on the prediction set. The prospective accuracy of the algorithm (Table 4) indicates that there is a small increase in the proportion of correctly classified low grade SILs and a small decrease in the proportion of correctly classified high grade SILs; there is approximately a 10% decrease in the proportion of correctly classified normal columnar tissues. Note that the majority of normal squamous tissues and samples with inflammation from both the calibration and prediction sets are misclassified as SIL using this algorithm. Evaluation of the misclassified SILs from the calibration set indicates that three samples with CIN II, three with CIN I and one with HPV are incorrectly classified. From the prediction set, two samples with CIN III, three with CIN II, and three with CIN I are incorrectly classified.

Classification in Calibration Set	Normal Squamous	Normal Columnar	Inflammation	LG SIL	HG SIL
Non SIL	7%	77%	27%	17%	9%
SIL	93%	23%	73%	83%	91%
Classification in Prediction Set	Normal Squamous	Normal Columnar	Inflammation	LG SIL	HG SIL
Non SIL	5%	64%	27%	13%	14%
SIL	95%	36%	73%	87%	86%

20 **Table 4.** Accuracy of *constituent* algorithm (2) which differentiates SILs and normal columnar tissues from the calibration and prediction sets. The first column corresponds to the spectroscopic classification and the first row corresponds to the histo-pathologic classification.

25 *Constituent algorithm (3) which differentiates High Grade SILs and Low Grade SILs.* A combination of normalized spectra at all three excitation wavelengths significantly enhanced the accuracy of the previously developed *constituent* algorithm (3)

- 40 -

which differentiated high SILs from low grade SILs using normalized spectra at 460 nm excitation. Multivariate statistical analysis of normalized spectra at all three excitation wavelengths resulted in four statistically significant principal components, that account collectively for 67% of the total variance of the spectral data set (Table 2). Again, a probability based classification algorithm was developed to differentiate high grade SILs from low grade SILs. The prior probability was: 40% low grade SILs and 60% high grade SILs. The optimal cost of misclassification of high grade SIL was equal to 0.51. Posterior probabilities of belonging to each tissue type were calculated. FIG. 8 illustrates the retrospective accuracy of the algorithm applied to the calibration data set. The posterior probability of being classified into the high grade SIL category is plotted for all SILs evaluated. FIG. 8 indicates that 83% of high grade SILs have a posterior probability greater than 0.5, and 70% of low grade SILs have a posterior probability less than 0.5.

The confusion matrix in Table 5 compares the retrospective accuracy of the *constituent* algorithm on the calibration set to its prospective accuracy on the prediction set. Its prospective accuracy indicates that there is a 5% decrease in the proportion of correctly classified low grade SILs and no change in the proportion of correctly classified high grade SILs. From the calibration set, six high grade SILs are misclassified; three samples with CIN III and three with CIN II are misclassified as low grade SIL. The misclassified low grade SILs comprise of five samples with CIN I and two with HPV. From the prediction set, five high grade SILs are misclassified; two have CIN III and three have CIN II. Of the ten misclassified low grade SILs from the prediction set, seven have CIN I and three have HPV.

Classification in Calibration Set	LG SIL	HG SIL
LG SIL	69%	17%
HG SIL	31%	83%
Classification in Prediction Set	LG SIL	HG SIL
LG SIL	63%	19%
HG SIL	37%	81%

Table 5. Accuracy of *constituent* algorithm (3) which differentiates high grade SILs and low grade SILs from the calibration and prediction sets. The first column corresponds to

the spectroscopic classification and the first row corresponds to the histo-pathologic classification.

5 *"Full-parameter" composite screening and diagnostic algorithms:* A composite screening algorithm was developed to differentiate SILs and non-SILs (normal squamous and columnar epithelia and inflammation) and a *composite* diagnostic algorithm was developed to differentiate high grade SILs from non-high grade SILs (low grade SILs, normal epithelia and inflammation). The effective accuracy of both *composite* algorithms were compared to those of the *constituent* algorithms from which they were
10 developed and to the accuracy of current detection modalities [5,9].

*A composite screening algorithm which discriminates between SILs and non
SILs:* A *composite* screening algorithm to differentiate SILs from non-SILs was developed using a combination of the two *constituent* algorithms: algorithm (1) which
15 differentiates SILs from normal squamous tissues and algorithm (2) which differentiates SILs from normal columnar epithelia. The optimal cost of misclassification of SIL was equal to 0.66 for *constituent* algorithm (1) and 0.64 for *constituent* algorithm (2). Only the costs of misclassification of SIL of the two *constituent* algorithms was altered for the development of the *composite* screening algorithm. These costs were selected to
20 minimize the total number of misclassified samples.

 The accuracy of the *composite* screening algorithm on the calibration and prediction data sets is illustrated in the confusion matrix in Table 6. Examination of the confusion matrix indicates that the algorithm correctly classifies approximately 90% of
25 high grade SILs and 75% of low grade SILs from the calibration data set. Furthermore, approximately, 80% of normal squamous tissues and 70% of normal columnar epithelia from the calibration set are correctly classified. Evaluation of the prediction set indicates that there is a small change in the proportion of correctly classified high grade SILs and low grade SILs. There is a negligible change in the correct classification of normal
30 squamous and columnar tissues. Note that while 80% of samples with inflammation from the calibration set are incorrectly classified as SIL, only 43% of these samples from the prediction set are incorrectly classified.

Classification in Calibration Set	Normal Squamous	Normal Columnar	Inflammation	LG SIL	HG SIL
Non SIL	79%	69%	20%	26%	11%
SIL	21%	31%	80%	74%	89%
Classification in Prediction Set	Normal Squamous	Normal Columnar	Inflammation	LG SIL	HG SIL
Non SIL	75%	69%	57%	25%	14%
SIL	25%	31%	43%	75%	86%

Table 6. Accuracy of the original *composite* algorithm which differentiates SILs and non SILs from the calibration and prediction sets. The first column corresponds to the spectroscopic classification and the first row corresponds to the histo-pathologic classification.

A comparison of the accuracy of the *composite* screening algorithm (Table 6) to that of each of the *constituent* algorithms (1) (Table 3) and (2) (Table 4) on the same spectral data set indicates that in general, there is less than a 10% decrease in the proportion of correctly classified SILs using the *composite* screening algorithm relative to using either of the *constituent* algorithms independently. Note, however, that the proportion of correctly classified normal (squamous and columnar) epithelia is substantially higher using the *composite* algorithm relative to using either of the *constituent* algorithms independently. These results confirm that utilization of a combination of the two *constituent* algorithms, significantly reduces the false-positive rate relative to that using each algorithm independently. Evaluation of the spectroscopically misclassified SILs from the calibration set (Table 6) indicates that only one sample with CIN III, three with CIN II, two with CIN I and four with HPV are incorrectly classified. From the prediction data set (Table 6), two samples with CIN III, four with CIN II, three with CIN I and one sample with HPV are incorrectly classified.

A composite diagnostic algorithm which differentiates High Grade SILs from non-High Grade SILs: A *composite* diagnostic algorithm which differentially detects high grade SILs was developed using a combination of all three *constituent* algorithms: algorithm (1) which differentiates SILs from normal squamous tissues, algorithm (2) which differentiates SILs from normal columnar epithelia and algorithm (3) which differentiates high grade SILs from low grade SILs. The optimal costs of

misclassification of SIL was equal to 0.87 for algorithm (1) and 0.65 for algorithm (2); the optimal cost of misclassification of high grade SIL was equal to 0.49 for algorithm (3). Only the costs of misclassification of SIL of *constituent* algorithms (1) and (2) and the cost of misclassification of high grade SIL of *constituent* algorithm (3) were altered during development of the *composite* diagnostic algorithm. These costs were selected to minimize the total number of misclassified samples.

The results of the *composite* diagnostic algorithm on the calibration and prediction sets are shown in the confusion matrix in Table 7. The algorithm correctly classifies 80% of high grade SILs, 74% of low grade SILs and more than 80% of normal epithelia. Evaluation of the prediction set using this *composite* algorithm indicates that there is only a 3% decrease in the proportion of correctly classified high grade SILs and a 7% decrease in the proportion of correctly classified low grade SILs. There is less than a 10% decrease in the proportion of correctly classified normal epithelia. A comparison between the calibration and prediction sets indicates that while more than 70% of samples with inflammation from the calibration data set are incorrectly classified as high grade SIL, only 14% of samples with inflammation from the prediction set are incorrectly identified. Due to the relatively small number of samples examined in this histo-pathologic category, the results presented here do not conclusively establish if the algorithm is capable of correctly identifying inflammation.

Classification in Calibration Set	Normal Squamous	Normal Columnar	Inflammation	LG SIL	HG SIL
Non HG SIL	84%	77%	27%	74%	20%
HG SIL	16%	23%	73%	26%	80%
Classification in Prediction Set	Normal Squamous	Normal Columnar	Inflammation	LG SIL	HG SIL
Non HG SIL	85%	69%	86%	67%	23%
HG SIL	15%	31%	14%	33%	77%

Table 7. Accuracy of the original *composite* screening algorithm which discriminates between high grade SILs and non-high grade SILs from the calibration and prediction sets. The first column corresponds to the spectroscopic classification and the first row corresponds to the histo-pathologic classification.

A comparison of the accuracy of the *composite* diagnostic algorithm to that of *constituent* algorithm (3) which differentiates high grade SILs from low grade SILs (Table 5) indicates there is less than a 5% decrease in the proportion of correctly classified high grade SILs and a 5% increase in the proportion of correctly classified low grade SILs using the *composite* diagnostic algorithm relative to using the *constituent* algorithm (3). Evaluation of the high grade SILs from the calibration set (Table 7) that were incorrectly classified indicates that three samples with CIN III and four with CIN II are incorrectly classified. From the prediction set, four samples with CIN III and five with CIN II are incorrectly classified.

"Reduced-parameter" composite screening and diagnostic algorithms:

Component Loadings. A component loading represents the correlation between each principal component and the original pre-processed fluorescence emission spectra at a particular excitation wavelength. FIGS. 9A, 9B and 9C illustrate component loadings of the diagnostically relevant principal components of *constituent* algorithm (1) obtained from normalized spectra at 337, 380 and 460 nm excitation, respectively. FIGS. 10A, 10B and 10C display component loadings that correspond to the diagnostically relevant principal components of *constituent* algorithm (2) obtained from normalized, mean-scaled spectra at 337, 380 and 460 nm excitation, respectively. Finally, FIGS. 11A, 11B and 11C display the component loadings corresponding to the diagnostically relevant principal components of *constituent* algorithm (3), obtained from normalized spectra at 337, 380 and 460 nm excitation, respectively. In each graph shown, the abscissa corresponds to the emission wavelength range at a particular excitation wavelength and the ordinate corresponds to the correlation coefficient of the component loading. Correlation coefficients of the component loading above 0.5 and below -0.5 are considered to be significant.

FIGS. 9A, 10A and 11A display component loadings of principal components of *constituent* algorithms (1), (2) and (3), respectively, obtained from pre-processed spectra at 337 nm excitation. A closer examination indicates that component loading 1 is nearly

- 45 -

identical for all three algorithms. Evaluation of this loading indicates that it is positively correlated with corresponding emission spectra over the wavelength range 360-440 nm and negatively correlated with corresponding emission spectra over the wavelength range 460-660 nm. All remaining principal components of all three algorithms display a correlation between -0.5 and 0.5, except component loading 4 of algorithm (2) (FIG. 10A) which displays a positive correlation of 0.75 with the corresponding emission spectra at 460 nm.

Figures 9B, 10B and 11B display component loadings that correspond to the diagnostically relevant principal components of *constituent* algorithms (1), (2) and (3), respectively obtained from pre-processed spectra at 380 nm excitation. Component loading 1 of all three algorithms is positively correlated with corresponding emission spectra over the wavelength range, 400-450 nm. Between 500-600 nm, only component loading 1 of algorithm (2) (FIG. 10B) is correlated negatively with corresponding emission spectra. However, examination of component loading 3 of algorithm (1) (FIG. 9B) and algorithm (3) (FIG. 11B) indicates that they are also negatively correlated with corresponding emission spectra from 500-600 nm. Only component loading 2 of algorithm (2) (FIG. 10B) is positively correlated with corresponding emission spectra from 500-600 nm. Also note that component loading 3 of algorithm (1) (FIG. 9B) and component loadings 3 and 6 of algorithm (3) (FIG. 11B) display a positive correlation with corresponding emission spectra at approximately 640 nm.

FIGS. 9C, 10C and 11C display component loadings that correspond to the diagnostic principal components of *constituent* algorithms (1), (2) and (3), respectively obtained from pre-processed spectra at 460 nm excitation. Note that only component loading 1 displays a negative correlation (< -0.5) with corresponding emission spectra for all three algorithms. This component loading is correlated with corresponding emission spectra over the wavelength range 580-660 nm. The remaining principal components of all three algorithms display a correlation between -0.5 and 0.5.

The component loadings at all three excitation wavelengths of all three *constituent* algorithms were evaluated to select fluorescence intensities at a minimum number of excitation-emission wavelength pairs required for the previously developed *constituent* and *composite* algorithms to perform with a minimal decrease in classification accuracy. Portions of the component loadings of the three *constituent* algorithms most highly correlated (correlation > 0.5 or < -0.5) with corresponding emission spectra at each excitation wavelength were selected and the reduced data matrix was then used to regenerate and evaluate the *constituent* and *composite* algorithms. It was iteratively determined that fluorescence intensities at a minimum of 15 excitation-emission wavelength pairs are required to re-develop *constituent* and *composite* algorithms that demonstrate a minimum decrease in classification accuracy. At 337 nm excitation, fluorescence intensities at two emission wavelengths between 360-450 nm and intensities at two emission wavelengths between 460-660 nm were selected. At 380 nm excitation, intensities at two emission wavelengths between 400-450 nm and intensities at four emission wavelengths between 500-640 nm were selected. Finally, at 460 nm excitation, fluorescence intensities at five emission wavelengths over the range 580-660 nm was selected. Table 8a lists these excitation-emission wavelength pairs for each of the three *constituent* algorithms, (1), (2) and (3). These excitation-emission wavelength pairs are also indicated on the component loading plots in FIGS. 9-11. The bandwidth at each emission wavelength is 10 nm.

Algorithm (1) (λ_{exc} , λ_{emm})	Algorithm (2) (λ_{exc} , λ_{emm})	Algorithm (3) (λ_{exc} , λ_{emm})
337, 410 nm	337, 410 nm	337, 410 nm
337, 430 nm	337, 430 nm	337, 430 nm
337, 460 nm	337, 460 nm	337, 460 nm
337, 510 nm	337, 510 nm	337, 510 nm
337, 580 nm	337, 580 nm	337, 580 nm
380, 410 nm	380, 410 nm	380, 410 nm
380, 430 nm	380, 430 nm	380, 430 nm
380, 460 nm	380, 460 nm	380, 460 nm
380, 510 nm	380, 510 nm	380, 510 nm
380, 580 nm	380, 580 nm	380, 580 nm
380, 640 nm	380, 600 nm	380, 640 nm
460, 510 nm	460, 510 nm	460, 510 nm
460, 580 nm	460, 580 nm	460, 580 nm
460, 600 nm	460, 600 nm	460, 600 nm
460, 620 nm	460, 620 nm	460, 620 nm
460, 640 nm	460, 660 nm	460, 640 nm

Table 8a. Fluorescence intensities at 18 excitation-emission wavelength pairs needed to re-develop the three *constituent* algorithms (1), (2) and (3) with a minimal decrease in classification accuracy.

5

Reduced-parameter composite algorithms: Using the fluorescence intensities only at the selected excitation-emission wavelength pairs, the three *constituent* algorithms were re-developed using the same formal analytical process as was done previously using the entire fluorescence emission spectra at all three excitation wavelengths (FIG. 2). The three *constituent* algorithms were then independently optimized using the calibration set and tested prospectively on the prediction data set. They were combined as described previously into *composite* screening and diagnostic algorithms. The effective accuracy of these reduced-parameter *composite* algorithms were compared to that of the full-parameter *composite* algorithms developed previously using fluorescence emission spectra at all three excitation wavelengths.

10

Excitation, Emission	Old Bandwidth (nm)	New Bandwidth (nm)
337 nm, 410 nm	10	80
337 nm, 430 nm	10	Eliminated
337 nm, 460 nm	10	20
337 nm, 510 nm	10	60
337 nm, 580 nm	10	60
380 nm, 410 nm	10	Eliminated
380 nm, 430 nm	10	Eliminated
380 nm, 510 nm	10	60
380 nm, 460 nm	10	20
380 nm, 580 nm	10	10
380 nm, 600 nm	10	10
380 nm, 640 nm	10	10
460 nm, 510 nm	10	10
460 nm, 580 nm	10	10
460 nm, 600 nm	10	10
460 nm, 620 nm	10	10
460 nm, 640 nm	10	10
460 nm, 660 nm	10	10

Table 8b. Fluorescence intensities at 15 excitation-emission wavelength pairs needed to re-develop the three *constituent* algorithms (1), (2) and (3) with a minimal decrease in classification accuracy.

Table 8b contains fluorescence intensities at 15 of the previous 18 excitation-emission wavelength pairs needed to redevelop the three constituent algorithms with a minimal decrease in classification accuracy. This table indicates that three variables are eliminated and the bandwidths of intensities at four excitation-emission wavelength pairs are increased by approximately a factor of four. These results establish that a further reduction in the number of emission variables and an increase in bandwidth minimally affect the classification accuracy of the algorithms. The benefit of eliminating the three emission variables and increasing the bandwidth of four emission variables is that it can reduce the total integration time needed to measure the fluorescence parameters from the tissue.

Table 9 displays the accuracy of the reduced-parameter *composite* screening algorithm (based on fluorescence intensities at 15 excitation-emission wavelength pairs) which discriminates between SILs and non-SILs applied to the calibration and prediction sets. A comparison between the calibration and prediction data sets indicates that there is less than a 10% decrease in the proportion of correctly classified SILs and normal squamous tissues from the prediction set. Note however that there is a 20% increase in the proportion of correctly classified normal columnar epithelia and a 40% increase in the proportion of correctly classified samples with inflammation from the prediction set.

Classification in Calibration Set	Normal Squamous	Normal Columnar	Inflammation	LG SIL	HG SIL
Non SIL	73%	46%	13%	17%	15%
SIL	27%	54%	87%	83%	85%
Classification in Prediction Set	Normal Squamous	Normal Columnar	Inflammation	LG SIL	HG SIL
Non SIL	72%	64%	50%	25%	11%
SIL	28%	36%	50%	75%	89%

Table 9. Accuracy of the reduced *composite* screening algorithm which differentiates SILs and non-SILs from the calibration and prediction sets. The first column corresponds to the spectroscopic classification and the first row corresponds to the histo-pathologic classification.

The accuracy of the reduced-parameter *composite* screening algorithm (Table 9) was compared to that of the full-parameter *composite* screening algorithm (Table 6) applied to the same spectral data set. A comparison indicates that in general there is less than a 10% decrease in the accuracy of the reduced-parameter *composite* algorithm relative to that of the full-parameter *composite* screening algorithm, except for a 20% decrease in the proportion of correctly classified normal columnar epithelia from the calibration set tested using the reduced-parameter *composite* screening algorithm (Table 9).

Table 10 displays the accuracy of the reduced-parameter *composite* diagnostic algorithm that differentially identifies high grade SILs from the calibration and prediction sets. A comparison of sample classification between the calibration and

prediction data sets indicates that there is negligible change in the proportion of correctly classified high grade, low grade SILs and normal squamous epithelia. Note that there is approximately a 20% increase in the proportion of correctly classified normal columnar epithelia and samples with inflammation from the prediction set.

Classification in Calibration Set	Normal Squamous	Normal Columnar	Inflammation	LG SIL	HG SIL
Non HG SIL	79%	62%	40%	65%	23%
HG SIL	21%	38%	60%	35%	77%
Classification in Prediction Set	Normal Squamous	Normal Columnar	Inflammation	LG SIL	HG SIL
Non HG SIL	82%	86%	64%	63%	20%
HG SIL	18%	14%	36%	37%	80%

Table 10. Accuracy of reduced *composite* diagnostic algorithm which differentiates high grade SILs from non-high grade SILs from the calibration and prediction sets. The first column corresponds to the spectroscopic classification and the first row corresponds to the histo-pathologic classification.

A comparison of the *composite* diagnostic algorithm based on the reduced emission variables (Table 10) to that using fluorescence emission spectra at all three excitation wavelengths (Table 7) applied to the same spectral data set indicates that in general, the accuracy of the reduced-parameter *composite* diagnostic algorithm is within 10% of that reported for the full-parameter *composite* diagnostic algorithm. However, a comparison between Tables 7 and 10 indicates that there is approximately a 15% decrease and a 20% increase in the proportion of correctly classified normal columnar epithelia from the calibration and prediction sets (Table 10), respectively which were tested using the reduced-parameter *composite* diagnostic algorithm. The opposite trend is observed for samples with inflammation tested using the reduced-parameter *composite* diagnostic algorithm (Table 10).

Table 11 compares the sensitivity and specificity of the full-parameter and reduced-parameter *composite* algorithms to that of Pap smear screening [5] and colposcopy in expert hands [9]. Table 11 indicates that the *composite* screening algorithms have a similar specificity and a significantly improved sensitivity relative to

Pap smear screening [5]. A comparison of the sensitivity of the *composite* screening algorithms to that of colposcopy in expert hands for differentiating SILs from non SILs indicates that these algorithms demonstrate a 10% decrease in sensitivity, but a 20% improvement in specificity. The *composite* diagnostic algorithms and colposcopy in expert hands discriminate high grade SILs from non-high grade SILs with a very similar sensitivity and specificity. A comparison between the full-parameter and reduced-parameter *composite* algorithms indicates that the algorithms based on the reduced emission variables demonstrate a similar classification accuracy relative to those that employ fluorescence emission spectra at all three excitation wavelengths.

Classification	SILs vs. NON SILs		HG SIL vs. Non HG SIL	
	Sensitivity	Specificity	Sensitivity	Specificity
Pap Smear	62%±23	68%±21	N/A	N/A
Colposcopy in Expert Hands	94%±6	48%±23	79%±23	76%±13
<i>Original Composite Algorithm</i>	82%±1.4	68%±0.0	79%±2	78%±6
<i>Reduced Composite Algorithm</i>	84%±1.5	65%±2	78%±0.7	74%±2

Table 11. Comparison of accuracy of *composite* screening and diagnostic algorithms to that of Pap smear screening and colposcopy in expert hands.

CLINICAL METHODS

In a clinical setting, the following exemplary steps are carried out to perform the composite screening algorithm in accordance with the present invention:

The instrument (FIG. 1) is turned on and calibrated. Next, the prior probability that the patient to be measured has SIL is entered. This probability may be derived from statistics from the general population, or may be derived from patient-specific data collected, for example, from a prior colposcopy. Next, a speculum is inserted and the cervix is observed. Acetic acid may be applied to the cervix, if desired.

The probe is directed to the cervix, ensuring that areas desired for screening will be illuminated. Multiple placements of the probe may be necessary. Using the probe, the cervix is illuminated with excitation at

- 52 -

approximately 337 nm, 380 nm and 460 nm. The probe will record resulting fluorescence data.

Data from each spatial location assessed is analyzed to indicate whether the tissue is SIL or not. Analysis steps carried out include:

1. Data recorded from each spatial location on the cervix is pre-processed in two ways: normalization, and normalization followed by mean scaling. Similarly pre-processed data obtained at each excitation wavelength are concatenated into a vector for each spatial location assessed.
2. The normalized data vector from each site (D_n') is multiplied by the reduced eigenvector matrix stored in memory (C_n'). C_n' contained only those eigenvectors which displayed statistically significant differences for samples to be classified by constituent algorithm 1.
3. The posterior probabilities that a sample is SIL or normal squamous epithelium are calculated using Bayes theorem. In this calculation, the mean values and standard deviations of the PC scores for normal squamous epithelium and SILs and optimal costs of misclassification stored in memory and the entered prior probability are used.
4. The normalized, mean-scaled prediction data vector (D_{nm}') is multiplied by the reduced eigenvector matrix from normalized, mean-scaled spectral data stored in memory (C_{nm}'). C_{nm}' contains only those eigenvectors which displayed statistically significant differences for samples to be classified by constituent algorithm 2.
5. The posterior probabilities that a sample is SIL or normal columnar epithelium are calculated using Bayes theorem. In this calculation, the

mean values and standard deviations of the PC scores for normal columnar epithelium and SILs and optimal costs of misclassification stored in memory and entered prior probabilities are used.

- 5 6. Using constituent algorithm 1, sites with a posterior probability of being normal squamous epithelium greater than a threshold value are classified as non-SIL. Remaining sites are classified based on the output of constituent algorithm 2. Using constituent algorithm 2, sample with a posterior probability of being normal columnar epithelium greater than a threshold are classified as non-SIL. The remaining samples are classified as SIL. These tissue classifications may then be displayed in an easily understandable way, for example, by displaying an image of the cervix with the different tissue types displayed as different colors.

10 To use the composite diagnostic algorithm of the present invention in clinical practice, the following exemplary steps are carried out:

15 The instrument (FIG. 1) is turned on and calibrated. The prior probability that the patient to be measured has SIL and HGSIL is entered. Once again, this probability may be derived from statistics from the general population, or may be derived from patient-specific data collected, for example, from a prior colposcopy. Next, a speculum is inserted and the cervix is observed. Acetic acid may be applied to the cervix, if desired.

20 The probe is directed to the cervix, ensuring that areas desired for screening will be illuminated. Multiple placements of the probe may be necessary. Using the probe, the cervix is illuminated with excitation at approximately 337 nm, 380 nm and 460 nm. The probe will record resulting fluorescence data.

25

30

Data from each spatial location assessed is analyzed to indicate whether the tissue is HGSIL or not. Analysis steps carried out include:

- 5 1. Data recorded from each spatial location on the cervix is pre-processed in two ways: normalization, and normalization followed by mean scaling. Similarly pre-processed data obtained at each excitation wavelength are concatenated into a vector for each spatial location assessed.
- 10 2. The normalized data vector from each site (D_n') is multiplied by the reduced eigenvector matrix stored in memory (C_n'). C_n' contained only those eigenvectors which displayed statistically significant differences for samples to be classified by constituent algorithm 1.
- 15 3. The posterior probabilities that a sample is SIL or normal squamous epithelium are calculated using Bayes theorem. In this calculation, the mean values and standard deviations of the PC scores for normal squamous epithelium and SILs and optimal costs of misclassification stored in memory and the entered prior probability are used.
- 20 4. The normalized, mean-scaled prediction data vector (D_{nm}') is multiplied by the reduced eigenvector matrix from normalized, mean-scaled spectral data stored in memory (C_{nm}'). C_{nm}' contains only those eigenvectors which displayed statistically significant differences
- 25 for samples to be classified by constituent algorithm 2.
- 30 5. The posterior probabilities that a sample is SIL or normal columnar epithelium are calculated using Bayes theorem. In this calculation, the mean values and standard deviations of the PC scores for normal columnar epithelium and SILs and optimal costs of misclassification stored in memory and entered prior probabilities are used.

5 6. The normalized prediction data vector (D_n') is multiplied by the reduced eigenvector matrix from normalized spectral data of the calibration set (C_n'). C_n' contains only those eigenvectors which displayed statistically significant differences for samples to be classified by constituent algorithm 3.

10 7. The posterior probabilities that a sample HGSIL or LGSIL are calculated using Bayes theorem. In this calculation, the mean values and standard deviations of the PC scores for HGSILs and LGSILs and optimal costs of misclassification stored in memory and entered prior probabilities are used.

15 8. Using constituent algorithm 1, sample with a posterior probability of being normal squamous epithelium greater than a threshold are classified as non-SIL. Remaining samples are classified based on the output of constituent algorithm 2. Using constituent algorithm 2, sample with a posterior probability of being normal columnar epithelium greater than a threshold are classified as non-SIL.
20 Remaining samples are classified based on the output of constituent algorithm 3. Using constituent algorithm 3, samples with a posterior probability of being LGSIL greater than a threshold are classified as LGSIL. The remaining samples are classified as HGSIL. These tissue classifications may then be displayed in an easily understandable way,
25 for example, by displaying an image of the cervix with the different tissue types displayed as different colors.

30 The present invention has been described with reference to particular exemplary embodiments. However it will be understood by those of ordinary skill in this technology that additions, deletions and changes may be made to the exemplary embodiments without departing from the scope of the present invention.

APPENDIX I: SPECIFICITY AND SENSITIVITY

Summarized from: Albert A., Harris E.K.: *Multivariate Interpretation of Clinical Laboratory Data*, Marcel Dekker Inc., New York, pp. 75-82, (1987), the disclosure of which is expressly incorporated herein by reference.

Assuming a group of T samples which can be categorized as normal (N samples) or diseased (D samples). A diagnostic test, designed to determine whether the sample is normal or diseased, is applied to each sample. The results of the tests is the continuous variable x , which is then used to determine the sample type. Figure 22 illustrates a hypothetical distribution of test values for each sample type. A diagnostic method based on this test can easily be defined by choosing a cutoff point, d , such that a sample with an observed value $x < d$ is diagnosed as normal and a sample with an observed value $x \geq d$ is diagnosed as abnormal.

Several quantitative measures have been defined to 'evaluate' the performance of this type of method. The first type evaluates the test itself (i.e. measures the ability of the test to separate the two populations, N and D). Sensitivity and specificity are two such measures. The second type is designed to aid in the interpretation of a particular test result (i.e. deciding whether the individual test measurement has come from a normal or diseased sample). Positive and negative predictive value are two measures of this type.

To define these measures, some terminology and notation must be introduced. Referring to Table 12, a sample to be tested can be either normal or diseased; the result of the test for each type of sample can be either negative or positive. True negatives represent those normal with a positive test result. In these cases, the diagnosis based on the test result is correct. False positives are those normal samples which have a positive test result and false negatives are those diseased samples which have a negative test result. In these cases, the diagnosis based on the test result is incorrect.

TABLE 12

	Normal	Diseased	Total Samples
Test Negative ($x < d$)	True Negatives (TN)	False Negatives (FN)	Negatives (Neg)
Test Positive ($x \geq d$)	False Positives (FP)	True Positives (TP)	Positives (Pos)
Total Samples	N	D	T

With this terminology, Table 13 contains a definition of sensitivity and specificity, the two measures which assess the performance of the diagnostic method. Specificity is the proportion of normal samples with a negative test result (proportion of normal samples diagnosed correctly). Sensitivity is the proportion of diseased samples with a positive test result (Proportion of diseased samples correctly diagnosed). Specificity represents the area under the normal sample distribution curve to the left of the cut off point while sensitivity represent the area under the diseased sample distribution curve to the right of the cut off point.

TABLE 13

Test Measure	Meaning	Calculation
Specificity	Proportion of normal samples with negative test result	$Sp = TN/N$
Sensitivity	Proportion of diseased samples with positive test result	$Se = TP/D$

While sensitivity and specificity characterize the performance of a particular method, another set of statistics is required to interpret the laboratory test result for a given specimen. The positive and negative predictive value quantify the meaning of an individual test result (Table 14). The positive predictive value is the probability that if the test result is positive, the sample is diseased. The negative predictive value is the probability that if the test result is negative, the sample is normal. Positive and negative predictive value are calculated from Bayes rule as outlined in Albert and Harris. Table

14 contains two equivalent formulas for calculation positive and negative predictive value.

TABLE 14

Measure	Meaning	Calculation 1	Calculation 2
Positive Predictive Value	The probability that, if the test is positive, the sample is diseased	$PV_+ = TP/Pos$	$PV_+ = DSe/(DSe + N(1 - Sp))$
Negative Predictive Value	The probability that, if the test is negative, the sample is normal	$PV_- = TN/Neg$	$PV_- = NSp/(NSp + D(1 - Se))$

APPENDIX II: PRINCIPAL COMPONENTS

5 Principal Components of Full-Parameter Constituent Algorithm 1 which differentiates SILs from Normal Squamous Tissues. Results reported for calibration set:

Legend	PC1	PC3	PC7
1	0.630	-0.576	0.288
1	0.590	-0.460	0.294
1	0.902	-0.849	-0.034
1	1.150	-0.678	-0.104
1	-0.413	-0.179	-0.150
1	-1.190	-0.171	-0.225
1	0.489	-0.049	-0.138
1	0.200	-0.163	-0.130
1	-0.889	-0.457	-0.104
1	1.060	-0.256	-0.253
1	1.290	-0.360	-0.143
1	-0.113	-0.220	-0.162
1	0.610	-0.108	-0.031
1	-1.460	-0.554	-0.129
1	0.468	-0.314	-0.262
1	1.290	-0.422	-0.093
1	0.174	-0.690	-0.156
1	0.428	-0.798	-0.225
1	1.290	-0.742	-0.362
1	1.410	-0.530	-0.154
1	0.284	-0.518	-0.331
1	2.220	-1.400	-0.137
1	1.160	-0.191	-0.116
1	0.231	-0.099	-0.247
1	1.640	-0.271	-0.249
1	0.538	-0.179	-0.112
1	-0.864	0.032	0.118
1	0.130	-0.273	-0.135
1	0.152	0.029	-0.010
1	-0.978	-0.702	0.095
1	0.635	-0.120	-0.079
1	1.660	-0.683	0.002
1	0.934	-0.401	-0.150
1	0.692	0.015	0.144
1	0.018	-0.363	-0.094
1	0.401	-0.085	0.071
1	0.187	-0.146	-0.043
1	0.132	-0.142	-0.175

- 60 -

Legend	PC1	PC3	PC7
1	-0.593	-1.260	-0.103
1	1.140	-0.565	-0.353
1	-0.349	-0.423	-0.147
1	0.717	-0.084	-0.373
1	-0.128	0.065	-0.141
1	1.570	-0.223	-0.171
1	1.500	-0.661	0.034
1	-1.210	-0.545	-0.126
1	-0.009	-0.104	-0.175
1	0.553	-0.169	-0.117
1	0.247	0.010	0.125
1	0.502	-0.182	-0.039
1	1.620	-0.247	-0.210
1	1.350	-0.546	-0.311
1	0.940	-0.690	-0.236
1	-0.258	-0.276	-0.033
1	0.369	-0.385	-0.347
1	-0.185	-0.227	-0.011
1	0.602	-0.642	-0.358
1	0.890	-0.963	-0.797
1	0.864	-0.463	-0.326
1	1.090	-0.548	-0.336
1	0.003	-0.152	-0.122
1	0.087	-0.153	-0.161
1	0.182	-0.315	-0.114
1	0.666	-0.437	-0.389
1	1.470	-0.874	-0.148
1	0.055	-0.492	-0.119
1	1.200	-0.728	-0.438
1	1.430	-0.442	-0.285
1	0.991	-0.580	-0.409
1	-0.454	-0.600	-0.174
1	0.659	-0.931	-0.505
1	0.225	-0.266	-0.351
1	-1.110	-0.519	-0.184
1	1.060	-0.390	-0.392
1	1.650	-0.584	-0.146
1	0.026	-0.048	-0.140
1	0.112	-0.466	-0.318
1	1.710	-0.561	-0.275
1	1.630	-0.918	-0.353
1	0.624	-0.490	-0.182
1	0.051	-0.922	-0.164
1	0.197	-0.004	0.003

- 61 -

Legend	PC1	PC3	PC7
1	-0.814	-0.239	0.066
1	-1.510	-0.399	0.135
1	0.403	-0.161	-0.281
1	0.043	-0.967	-0.132
1	-1.940	-1.510	-0.130
1	-0.980	-0.603	0.107
1	0.468	-0.327	-0.141
1	0.174	-1.140	0.033
1	1.220	-0.413	-0.340
1	1.110	-0.272	-0.135
1	0.096	-0.299	-0.195
1	-1.190	-0.083	-0.324
2	-0.642	-0.115	-0.100
2	-0.421	-0.074	-0.194
2	-0.170	-0.293	-0.344
2	-1.680	-1.210	-0.469
2	-0.828	-0.215	-0.426
2	-0.327	-0.096	-0.287
2	-1.690	-0.350	-0.090
2	-1.330	-0.709	-0.367
2	-0.481	0.261	-0.238
2	-0.623	-0.126	0.095
2	0.035	-0.325	-0.319
2	-0.809	-0.255	-0.329
2	-0.764	-0.153	-0.095
3	-1.850	-1.730	0.225
3	-0.299	-0.487	0.162
3	-0.205	-0.496	-0.077
3	1.990	-1.760	-0.094
3	-0.612	-0.292	-0.084
3	-1.110	-1.070	-0.083
3	-1.300	-0.330	-0.103
3	-0.176	-0.114	0.061
3	-1.460	-0.228	-0.519
3	-0.435	-0.881	-0.072
4	-0.286	-0.057	0.141
4	-1.080	-0.546	-0.247
4	-1.140	-0.573	-0.438
4	-0.649	-0.848	0.010
4	-1.770	-1.110	-0.186
4	-1.140	-0.881	-0.392
4	1.940	-1.980	0.130
4	-0.839	-0.500	-0.069
4	-1.550	-0.608	-0.328

- 62 -

Legend	PC1	PC3	PC7
4	-0.263	-0.158	-0.309
4	1.590	-0.250	-0.311
4	-1.030	-0.353	-0.182
4	-1.420	-0.641	-0.278
4	-0.864	-0.313	-0.018
4	-0.095	-0.982	0.087
5	0.415	-0.346	-0.154
5	-1.320	-0.560	-0.359
5	0.716	-0.066	0.068
5	-1.010	-0.403	-0.571
5	-0.057	-1.040	-0.162
5	0.067	-0.471	-0.615
5	0.702	-1.080	-0.830
5	0.297	-0.568	0.185
5	-0.403	-0.508	-0.164
5	1.060	-1.030	-0.079
5	-0.971	-0.624	-0.294
5	-1.300	-0.254	-0.693
5	-1.200	-0.041	-0.474
5	-0.276	0.347	-0.453
5	0.183	-0.273	-0.343
5	-0.616	-0.661	-0.506
5	-0.318	-0.323	-0.240
5	-0.406	-0.773	-0.154
5	-0.451	-0.297	-0.447
5	0.557	-0.088	-0.262
5	-0.208	-0.863	-0.223
5	-0.258	0.027	-0.437
5	-0.400	-0.813	-0.122
6	-0.382	-1.460	0.152
6	-1.370	-0.247	-0.609
6	-0.616	-0.256	-0.112
6	0.390	-0.182	-0.235
6	-0.546	-0.424	-0.129
6	0.768	-1.170	-0.515
6	-0.770	-0.906	-0.002
6	-1.810	-0.883	-0.097
6	0.026	-1.210	-0.334
6	-1.060	-0.393	-0.111
6	-1.370	-0.783	-0.251
6	0.880	-0.476	-0.368
6	-0.589	-0.346	-0.384
6	0.662	-1.040	-0.347
6	-0.292	-0.048	-0.470

- 63 -

Legend	PC1	PC3	PC7
6	-0.106	-0.239	-0.073
6	-1.020	-0.816	-0.129
6	-0.484	-0.425	-0.207
6	-0.834	-0.521	-0.006
6	-1.340	-1.860	-0.283
6	-0.084	-0.197	-0.125
6	-0.733	-0.689	-0.253
6	-0.788	-0.409	-0.028
6	-1.280	-1.410	-0.298
6	-0.816	-0.099	-0.078
6	-1.160	-1.060	0.185
6	-0.434	-0.092	-0.075
6	-0.139	-1.300	-0.195
6	-0.768	0.120	-0.300
6	-0.951	-0.441	-0.219
6	-0.392	-0.307	-0.727
6	-0.015	0.071	-0.171
6	-1.430	-0.619	-0.127
6	-1.110	-1.070	-0.104
6	-1.360	-0.504	-0.699

Principal Components of Full-Parameter Constituent Algorithm 2 which differentiates SILs from Normal Columnar Tissues. Results reported for calibration set:

L	PC1	PC2	PC4	PC5
1	0.413	-0.096	-0.067	-0.134
1	0.763	-0.119	-0.089	0.078
1	0.674	0.403	-0.184	0.040
1	1.100	0.472	-0.308	0.210
1	0.381	0.166	0.253	-0.064
1	-0.309	-0.278	-0.048	-0.080
1	0.664	-0.169	-0.038	-0.021
1	-0.083	-0.204	0.161	-0.003
1	-1.210	-0.193	-0.096	-0.109
1	0.053	-0.105	0.207	0.083
1	0.258	-0.055	0.162	-0.217
1	0.021	-0.009	-0.110	0.127
1	0.357	0.091	0.072	0.112
1	-1.020	-0.412	-0.765	-0.043
1	-0.089	-0.065	-0.025	0.045
1	0.842	0.141	-0.168	-0.017
1	0.020	0.016	0.009	0.047
1	0.263	0.199	0.016	0.127
1	1.190	0.055	-0.406	-0.087
1	0.913	0.102	-0.215	-0.359
1	0.685	0.127	0.152	0.159
1	0.224	-0.241	0.032	0.071
1	1.070	0.314	-0.017	-0.022
1	0.914	-0.262	0.391	-0.103
1	1.790	-0.233	-0.561	-0.166
1	0.557	0.127	-0.101	0.017
1	-0.310	-0.323	-0.217	-0.136
1	0.422	0.134	0.046	0.005
1	0.164	-0.325	0.074	0.010
1	-1.050	0.274	-0.081	-0.224
1	0.845	-0.057	-0.089	0.163
1	0.733	-0.462	-0.653	-0.422
1	0.084	-0.271	0.128	0.041
1	0.792	-0.338	0.092	-0.166
1	0.560	0.264	0.209	-0.040
1	0.535	0.180	0.189	0.013
1	0.318	0.209	0.133	0.137
1	0.521	0.174	0.058	0.179
1	0.067	0.747	-0.188	0.072
1	1.300	-0.134	-0.288	-0.060
1	-0.049	0.134	0.312	-0.153

- 65 -

L	PC1	PC2	PC4	PC5
1	0.494	0.152	0.079	0.033
1	0.183	-0.462	0.144	0.071
1	1.420	0.051	-0.340	-0.033
1	1.300	-0.384	-0.421	-0.279
1	-0.383	0.239	-0.255	-0.165
1	0.341	-0.111	-0.067	0.114
1	0.443	0.169	0.408	0.132
1	0.289	-0.053	0.099	0.016
1	1.210	-0.378	0.141	0.187
1	1.060	0.199	-0.337	-0.096
1	0.631	-0.161	-0.164	-0.054
1	0.795	0.417	-0.069	0.166
1	0.209	0.189	0.050	0.012
1	1.080	-0.132	0.267	-0.027
1	0.425	0.065	0.001	0.217
1	0.079	0.044	-0.094	0.066
1	0.275	0.053	-0.175	-0.043
1	0.843	0.151	-0.142	0.129
1	1.550	0.030	-0.181	0.243
1	0.626	-0.096	0.135	0.033
1	0.482	-0.093	0.075	0.070
1	0.599	-0.019	0.143	0.048
1	0.849	0.389	-0.038	0.100
1	0.494	-0.108	-0.082	-0.002
1	0.505	-0.274	0.209	-0.007
1	1.470	-0.026	-0.380	-0.059
1	1.050	0.296	-0.017	-0.050
1	0.845	-0.148	-0.065	-0.001
1	-0.030	0.380	0.107	-0.095
1	0.405	0.217	-0.119	0.186
1	0.563	-0.104	0.039	0.131
1	-0.809	-0.244	-0.451	0.206
1	0.552	0.085	-0.066	0.107
1	1.070	-0.184	-0.589	-0.234
1	0.312	-0.133	-0.028	0.084
1	0.183	0.048	0.129	0.003
1	1.410	0.112	-0.637	-0.194
1	0.852	-0.304	-0.304	-0.381
1	0.508	-0.419	0.008	-0.018
1	0.257	0.368	-0.054	0.018
1	0.573	0.077	-0.080	0.010
1	-0.156	-0.155	-0.338	0.124
1	-0.885	-0.231	-0.527	-0.055
1	0.313	-0.447	0.072	0.271

- 66 -

L	PC1	PC2	PC4	PC5
1	0.103	0.574	0.086	0.037
1	0.151	0.359	0.135	-0.162
1	0.129	0.140	0.188	-0.140
1	-0.081	-0.156	0.219	0.155
1	0.093	0.716	-0.151	-0.032
1	0.265	-0.348	0.374	0.251
1	0.674	-0.365	-0.125	-0.049
1	0.457	-0.110	0.050	0.070
1	0.089	-0.378	-0.401	0.031
2	-0.616	-0.363	-0.106	0.101
2	-0.258	-0.340	-0.080	-0.043
2	-0.543	-0.072	-0.197	-0.002
2	-1.190	0.109	-0.003	0.020
2	-0.407	-0.526	0.177	-0.005
2	-0.123	-0.199	0.107	0.142
2	-0.813	-0.344	-0.523	0.010
2	-1.180	-0.174	0.041	-0.079
2	-0.677	-0.544	-0.032	-0.061
2	-0.603	-0.250	-0.259	0.088
2	-0.323	0.114	0.197	0.061
2	-1.290	-0.338	0.078	-0.082
2	-0.968	-0.028	0.228	0.046
3	-0.714	0.263	-0.224	0.128
3	-0.432	-0.297	0.090	-0.260
3	-0.246	0.003	0.116	0.079
3	-0.045	0.128	0.036	0.090
3	-0.087	0.367	0.180	0.018
3	-0.988	0.348	0.061	-0.227
3	-1.470	-0.567	-0.515	-0.060
3	-0.260	-0.288	0.266	-0.152
3	-1.800	-0.666	-0.386	-0.044
3	-0.163	0.543	0.082	-0.165
4	-0.446	-0.511	0.187	-0.238
4	-0.224	0.330	0.114	0.034
4	-1.030	0.176	-0.054	0.084
4	-0.730	0.394	0.214	-0.147
4	-1.440	0.154	-0.394	-0.036
4	-0.771	0.256	0.054	0.055
4	-0.127	0.288	-0.166	0.085
4	-0.672	0.244	0.185	-0.124
4	-0.671	0.193	-0.103	0.078
4	0.060	-0.285	0.133	0.006
4	1.020	0.142	-0.438	-0.001
4	-0.425	-0.080	-0.119	0.006

- 67 -

L	PC1	PC2	PC4	PC5
4	-0.999	0.142	-0.198	0.047
4	0.268	-0.186	0.184	-0.075
4	-0.717	0.356	-0.096	0.030
5	0.240	-0.121	0.021	0.126
5	-0.593	0.039	-0.421	0.007
5	0.372	-0.086	-0.063	-0.200
5	-1.480	-0.321	-0.188	0.232
5	-0.954	0.501	0.298	0.105
5	-0.442	-0.102	0.232	0.014
5	-0.073	0.109	0.100	0.315
5	0.265	0.389	0.032	-0.144
5	-0.276	0.371	0.166	-0.075
5	-0.055	0.431	-0.243	-0.376
5	-0.451	-0.360	0.221	-0.354
5	-1.040	-0.285	-0.166	0.302
5	-0.642	-0.475	0.058	0.085
5	-0.755	-0.254	0.592	0.010
5	-0.490	-0.434	0.179	0.045
5	0.063	-0.043	0.092	0.089
5	-0.327	-0.135	0.005	-0.019
5	0.043	0.292	0.345	-0.252
5	-0.109	-0.355	0.106	0.298
5	1.010	-0.267	-0.130	0.085
5	-0.457	0.147	0.117	-0.196
5	0.130	0.181	0.331	0.119
5	-0.551	0.157	0.103	-0.121
6	-0.668	1.010	0.133	0.016
6	-0.601	-0.219	-0.273	0.268
6	-0.488	-0.070	-0.079	-0.058
6	0.045	0.046	0.046	-0.072
6	-0.278	0.004	-0.230	-0.055
6	-0.156	0.620	0.129	0.208
6	-0.553	0.533	0.069	-0.216
6	-1.190	-0.493	-0.774	0.083
6	-0.735	0.701	0.163	-0.019
6	-0.619	0.066	-0.068	-0.078
6	-0.926	0.028	0.101	-0.023
6	0.361	0.116	-0.041	-0.064
6	-0.339	0.180	0.181	-0.054
6	0.488	0.172	-0.086	0.000
6	-0.271	-0.517	0.171	0.199
6	0.269	-0.207	0.095	-0.099
6	-0.136	0.233	0.077	-0.103
6	0.066	-0.330	0.455	-0.310

- 68 -

L	PC1	PC2	PC4	PC5
6	-0.660	0.283	0.093	-0.132
6	-1.400	1.460	-0.371	0.665
6	0.296	0.131	-0.031	0.090
6	-0.235	-0.047	-0.327	0.147
6	-0.529	-0.019	0.127	-0.117
6	-1.510	0.623	0.091	0.344
6	0.064	-0.064	-0.030	-0.076
6	-0.373	1.040	-0.099	-0.280
6	-0.075	-0.130	0.077	-0.130
6	0.479	0.206	-0.047	0.080
6	-0.092	-0.433	0.087	0.045
6	-0.364	0.010	-0.046	0.126
6	-1.220	-0.321	0.804	0.698
6	-0.196	-0.155	0.300	0.123
6	-0.347	-0.111	-0.024	-0.097
6	-0.479	-0.206	0.047	-0.080
6	-0.078	0.406	0.047	0.227

Principal Components of Full-Parameter Constituent Algorithm 3 which differentiates HG SILs from LG SILs. Results reported for calibration set.

L	PC1	PC3	PC6	PC8
1	0.630	-0.576	-0.733	-0.127
1	0.590	-0.460	-0.800	-0.113
1	0.902	-0.849	-0.480	-1.080
1	1.150	-0.678	-1.070	-0.601
1	-0.413	-0.179	-0.777	-0.231
1	-1.190	-0.171	-0.859	-0.273
1	0.489	-0.049	-0.676	-0.292
1	0.200	-0.163	-0.819	-0.476
1	-0.889	-0.457	-0.883	-0.420
1	1.060	-0.256	-0.807	-0.268
1	1.290	-0.360	-0.860	-0.321
1	-0.113	-0.220	-0.879	-0.511
1	0.610	-0.108	-0.927	-0.446
1	-1.460	-0.554	-1.050	-0.356
1	0.468	-0.314	-1.010	-0.557
1	1.290	-0.422	-0.800	-0.340
1	0.174	-0.690	-0.966	-0.505
1	0.428	-0.798	-0.975	-0.517
1	1.290	-0.742	-0.809	-0.214
1	1.410	-0.530	-0.942	-0.253
1	0.284	-0.518	-0.950	-0.454
1	2.220	-1.400	-0.802	-0.765
1	1.160	-0.191	-0.919	-0.652
1	0.231	-0.099	-0.907	-0.476
1	1.640	-0.271	-0.678	-0.411
1	0.538	-0.179	-0.942	-0.693
1	-0.864	0.032	-0.905	-0.388
1	0.130	-0.273	-1.110	-0.464
1	0.152	0.029	-0.958	-0.725
1	-0.978	-0.702	-1.240	-0.666
1	0.635	-0.120	-0.823	-0.554
1	1.660	-0.683	-0.848	-0.439
1	0.934	-0.401	-0.956	-0.532
1	0.692	0.015	-0.850	-0.492
1	0.018	-0.363	-0.938	-0.491
1	0.401	-0.085	-0.984	-0.561
1	0.187	-0.146	-1.030	-0.532
1	0.132	-0.142	-1.050	-0.625
1	-0.593	-1.260	-1.070	-0.557
1	1.140	-0.565	-0.758	-0.378
1	-0.349	-0.423	-0.766	-0.458

- 70 -

L	PC1	PC3	PC6	PC8
1	0.717	-0.084	-0.918	-0.529
1	-0.128	0.065	-0.820	-0.553
1	1.570	-0.223	-0.801	-0.474
1	1.500	-0.661	-0.754	-0.278
1	-1.210	-0.545	-0.776	-0.353
1	-0.009	-0.104	-0.816	-0.518
1	0.553	-0.169	-0.939	-0.618
1	0.247	0.010	-0.968	-0.611
1	0.502	-0.182	-1.010	-0.522
1	1.620	-0.247	-0.887	-0.497
1	1.350	-0.546	-0.791	-0.528
1	0.940	-0.690	-1.040	-0.574
1	-0.258	-0.276	-1.020	-0.645
1	0.369	-0.385	-0.836	-0.745
1	-0.185	-0.227	-1.060	-0.527
1	0.602	-0.642	-0.865	-0.293
1	0.890	-0.963	-1.510	-0.591
1	0.864	-0.463	-1.050	-0.461
1	1.090	-0.548	-0.932	-0.358
1	0.003	-0.152	-0.927	-0.361
1	0.087	-0.153	-0.861	-0.595
1	0.182	-0.315	-0.965	-0.411
1	0.666	-0.437	-0.994	-0.330
1	1.470	-0.874	-0.725	-0.089
1	0.055	-0.492	-1.000	-0.383
1	1.200	-0.728	-0.907	-0.348
1	1.430	-0.442	-0.902	-0.446
1	0.991	-0.580	-0.889	-0.315
1	-0.454	-0.600	-1.040	-0.611
1	0.659	-0.931	-0.672	-0.599
1	0.225	-0.266	-0.918	-0.373
1	-1.110	-0.519	-0.988	-0.279
1	1.060	-0.390	-0.991	-0.485
1	1.650	-0.584	-0.973	-0.558
1	0.026	-0.048	-0.880	-0.406
1	0.112	-0.466	-0.980	-0.447
1	1.710	-0.561	-0.755	-0.408
1	1.630	-0.918	-1.230	-0.470
1	0.624	-0.490	-0.944	-0.599
1	0.051	-0.922	-0.990	-0.450
1	0.197	-0.004	-0.908	-0.510
1	-0.814	-0.239	-0.815	-0.289
1	-1.510	-0.399	-0.932	-0.328
1	0.403	-0.161	-1.000	-0.616

- 71 -

L	PC1	PC3	PC6	PC8
1	0.043	-0.967	-0.972	-0.665
1	-1.940	-1.510	-0.728	-0.651
1	-0.980	-0.603	-0.988	-0.440
1	0.468	-0.327	-0.855	-0.442
1	0.174	-1.140	-0.843	-0.627
1	1.220	-0.413	-0.873	-0.518
1	1.110	-0.272	-0.801	-0.410
1	0.096	-0.299	-0.956	-0.524
1	-1.190	-0.083	-0.928	-0.501
2	-0.642	-0.115	-0.891	-0.659
2	-0.421	-0.074	-0.746	-0.336
2	-0.170	-0.293	-0.999	-0.479
2	-1.680	-1.210	-0.052	-0.787
2	-0.828	-0.215	-0.730	-0.495
2	-0.327	-0.096	-0.893	-0.541
2	-1.690	-0.350	-1.570	0.044
2	-1.330	-0.709	-0.869	-0.413
2	-0.481	0.261	-0.864	-0.420
2	-0.623	-0.126	-0.913	-0.550
2	0.035	-0.325	-0.990	-0.496
2	-0.809	-0.255	-0.765	-0.478
2	-0.764	-0.153	-0.959	-0.573
3	-1.850	-1.730	-1.060	-1.300
3	-0.299	-0.487	-0.796	-0.542
3	-0.205	-0.496	-0.880	-0.481
3	1.990	-1.760	-0.752	-0.609
3	-0.612	-0.292	-1.150	-0.562
3	-1.110	-1.070	-0.996	-0.604
3	-1.300	-0.330	-1.240	-0.852
3	-0.176	-0.114	-0.995	-0.616
3	-1.460	-0.228	-1.110	-0.520
3	-0.435	-0.881	-1.090	-0.533
4	-0.286	-0.057	-0.928	-0.711
4	-1.080	-0.546	-0.964	-0.488
4	-1.140	-0.573	-1.030	-0.261
4	-0.649	-0.848	-1.060	-0.411
4	-1.770	-1.110	-0.822	-0.476
4	-1.140	-0.881	-0.894	-0.408
4	1.940	-1.980	-0.856	-0.521
4	-0.839	-0.500	-0.955	-0.571
4	-1.550	-0.608	-1.180	-0.232
4	-0.263	-0.158	-0.744	-0.297
4	1.590	-0.250	-0.869	-0.474
4	-1.030	-0.353	-0.739	-0.284

- 72 -

L	PC1	PC3	PC6	PC8
4	-1.420	-0.641	-1.030	-0.377
4	-0.864	-0.313	-1.090	-0.495
4	-0.095	-0.982	-1.050	-0.451
5	0.415	-0.346	-0.649	-0.850
5	-1.320	-0.560	-0.940	-0.282
5	0.716	-0.066	-0.872	-0.464
5	-1.010	-0.403	-1.070	-0.492
5	-0.057	-1.040	-1.090	-0.594
5	0.067	-0.471	-1.020	-0.277
5	0.702	-1.080	-1.610	-0.545
5	0.297	-0.568	-1.020	-0.626
5	-0.403	-0.508	-0.966	-0.386
5	1.060	-1.030	-1.030	-0.227
5	-0.971	-0.624	-0.731	-0.284
5	-1.300	-0.254	-1.590	-0.970
5	-1.200	-0.041	-1.020	-0.759
5	-0.276	0.347	-0.762	-0.781
5	0.183	-0.273	-0.794	-0.676
5	-0.616	-0.661	-0.989	-0.818
5	-0.318	-0.323	-1.130	-0.570
5	-0.406	-0.773	-0.981	-0.286
5	-0.451	-0.297	-1.050	-0.430
5	0.557	-0.088	-0.927	-0.665
5	-0.208	-0.863	-0.967	-0.484
5	-0.258	0.027	-0.908	-0.372
5	-0.400	-0.813	-0.967	-0.583
6	-0.382	-1.460	-0.829	-0.076
6	-1.370	-0.247	-0.950	-0.132
6	-0.616	-0.256	-0.867	-0.432
6	0.390	-0.182	-0.796	-0.355
6	-0.546	-0.424	-1.200	-0.654
6	0.768	-1.170	-1.140	-0.381
6	-0.770	-0.906	-0.862	-0.358
6	-1.810	-0.883	-1.110	-0.225
6	0.026	-1.210	-0.959	-0.584
6	-1.060	-0.393	-0.945	-0.578
6	-1.370	-0.783	-0.837	-0.544
6	0.880	-0.476	-0.936	-0.372
6	-0.589	-0.346	-1.040	-0.451
6	0.662	-1.040	-0.993	-0.515
6	-0.292	-0.048	-0.985	-0.457
6	-0.106	-0.239	-0.796	-0.440
6	-1.020	-0.816	-0.936	-0.213
6	-0.484	-0.425	-0.757	-0.417

- 73 -

L	PC1	PC3	PC6	PC8
6	-0.834	-0.521	-1.000	-0.586
6	-1.340	-1.860	-0.571	-0.439
6	-0.084	-0.197	-1.010	-0.541
6	-0.733	-0.689	-1.050	-0.421
6	-0.788	-0.409	-0.958	-0.358
6	-1.280	-1.410	-1.210	-0.353
6	-0.816	-0.099	-0.780	-0.370
6	-1.160	-1.060	-1.060	-0.531
6	-0.434	-0.092	-0.785	-0.477
6	-0.139	-1.300	-0.827	-0.555
6	-0.768	0.120	-0.628	-0.568
6	-0.951	-0.441	-1.110	-0.085
6	-0.392	-0.307	-0.411	-0.213
6	-0.015	0.071	-0.829	-0.420
6	-1.430	-0.619	-1.150	-0.767
6	-1.110	-1.070	-0.843	-0.648
6	-1.360	-0.504	-0.251	-0.591
	-1.940	-1.980	-1.610	-1.300

Principal Components of Reduced-Parameter Constituent Algorithm 1 which differentiates SILs from Normal Squamous Tissues. Results reported for calibration set.

L	PC1	PC2	PC3	PC4	PC6
1	0.748	-1.370	0.432	-0.128	-0.580
1	0.747	-1.380	0.432	-0.128	-0.602
1	0.857	-1.490	0.644	-0.281	-0.410
1	0.937	-1.410	0.678	-0.111	-0.615
1	0.513	-1.310	0.791	-0.172	-0.572
1	0.150	-1.190	0.803	-0.165	-0.552
1	0.828	-1.280	0.772	-0.179	-0.553
1	0.768	-1.370	0.870	-0.187	-0.568
1	0.334	-1.350	0.819	-0.183	-0.606
1	0.929	-1.340	0.657	-0.183	-0.589
1	0.989	-1.300	0.676	-0.143	-0.577
1	0.584	-1.320	0.789	-0.170	-0.590
1	0.807	-1.300	0.716	-0.165	-0.584
1	-0.221	-1.050	0.509	-0.117	-0.515
1	0.729	-1.360	0.699	-0.146	-0.575
1	0.969	-1.320	0.646	-0.158	-0.575
1	0.701	-1.450	0.734	-0.056	-0.563
1	0.773	-1.490	0.722	-0.071	-0.577
1	0.878	-1.270	0.697	-0.173	-0.622
1	0.766	-1.120	0.535	-0.141	-0.550
1	0.645	-1.370	0.690	-0.125	-0.534
1	0.741	-0.828	0.386	-0.060	-0.589
1	0.972	-1.270	0.761	-0.146	-0.541
1	0.680	-1.260	0.774	-0.179	-0.578
1	0.993	-1.100	0.718	-0.213	-0.566
1	0.848	-1.340	0.819	-0.130	-0.508
1	0.316	-1.180	0.794	-0.125	-0.533
1	0.579	-1.310	0.730	-0.077	-0.535
1	0.738	-1.250	0.851	-0.083	-0.509
1	0.303	-1.370	0.816	0.046	-0.575
1	0.862	-1.290	0.736	-0.124	-0.524
1	0.975	-1.140	0.635	-0.116	-0.564
1	0.935	-1.330	0.763	-0.065	-0.530
1	0.897	-1.270	0.703	-0.111	-0.528
1	0.697	-1.380	0.821	-0.085	-0.551
1	0.789	-1.300	0.724	-0.075	-0.523
1	0.701	-1.320	0.700	-0.073	-0.536
1	0.676	-1.340	0.765	-0.110	-0.541
1	0.433	-1.540	0.666	0.109	-0.541
1	0.910	-1.340	0.776	-0.315	-0.621
1	0.557	-1.370	0.781	-0.099	-0.481

- 75 -

L	PC1	PC2	PC3	PC4	PC6
1	0.923	-1.300	0.873	-0.105	-0.514
1	0.628	-1.210	0.845	-0.101	-0.473
1	1.060	-1.170	0.705	-0.141	-0.543
1	0.897	-1.140	0.598	-0.167	-0.600
1	0.143	-1.310	0.845	-0.269	-0.687
1	0.635	-1.310	0.807	-0.185	-0.568
1	0.867	-1.360	0.763	-0.069	-0.531
1	0.771	-1.250	0.769	-0.051	-0.472
1	0.763	-1.330	0.681	-0.114	-0.552
1	1.060	-1.170	0.697	-0.135	-0.522
1	1.040	-1.330	0.754	-0.143	-0.568
1	0.898	-1.430	0.724	-0.096	-0.574
1	0.558	-1.330	0.789	-0.059	-0.487
1	0.668	-1.340	0.771	-0.192	-0.536
1	0.582	-1.320	0.713	0.020	-0.537
1	0.771	-1.440	0.656	-0.164	-0.597
1	0.635	-1.280	0.691	-0.059	-0.559
1	0.854	-1.400	0.686	-0.126	-0.585
1	0.876	-1.360	0.640	-0.142	-0.599
1	0.679	-1.260	0.784	0.006	-0.511
1	0.690	-1.320	0.834	-0.146	-0.491
1	0.711	-1.340	0.753	-0.096	-0.524
1	0.694	-1.300	0.677	-0.099	-0.546
1	0.812	-1.160	0.545	-0.188	-0.640
1	0.671	-1.390	0.754	-0.054	-0.556
1	0.869	-1.300	0.844	-0.337	-0.660
1	1.000	-1.300	0.724	-0.160	-0.568
1	0.860	-1.350	0.693	-0.166	-0.576
1	0.476	-1.340	0.738	0.152	-0.500
1	0.804	-1.500	0.728	-0.141	-0.576
1	0.729	-1.330	0.790	-0.069	-0.509
1	0.167	-1.360	0.671	-0.096	-0.558
1	0.929	-1.330	0.733	-0.087	-0.542
1	0.933	-1.110	0.651	-0.113	-0.562
1	0.581	-1.270	0.710	-0.182	-0.577
1	0.655	-1.370	0.765	-0.077	-0.570
1	0.921	-1.070	0.652	-0.187	-0.548
1	0.753	-1.010	0.620	-0.111	-0.522
1	0.730	-1.320	0.687	-0.124	-0.546
1	0.615	-1.430	0.692	-0.014	-0.552
1	0.640	-1.150	0.655	-0.012	-0.445
1	0.155	-1.200	0.583	-0.225	-0.573
1	-0.120	-1.140	0.592	-0.191	-0.573
1	0.694	-1.280	0.727	-0.123	-0.544

L	PC1	PC2	PC3	PC4	PC6
1	0.556	-1.460	0.645	-0.043	-0.506
1	-0.245	-1.390	0.594	-0.170	-0.560
1	0.126	-1.310	0.639	-0.083	-0.486
1	0.726	-1.330	0.668	-0.131	-0.559
1	0.633	-1.490	0.669	-0.076	-0.568
1	0.879	-1.260	0.732	-0.224	-0.559
1	0.898	-1.260	0.606	-0.183	-0.567
1	0.641	-1.290	0.788	-0.113	-0.552
1	-0.132	-0.941	0.564	-0.168	-0.439
2	0.407	-1.260	0.803	-0.116	-0.546
2	0.494	-1.260	0.841	-0.228	-0.586
2	0.474	-1.350	0.762	-0.273	-0.653
2	0.009	-1.650	0.734	-0.455	-0.352
2	0.254	-1.280	0.903	-0.364	-0.616
2	0.496	-1.250	0.868	-0.143	-0.534
2	-0.170	-1.120	0.642	0.053	-0.728
2	0.179	-1.460	0.977	-0.370	-0.650
2	0.490	-1.170	0.905	-0.200	-0.513
2	0.383	-1.240	0.739	-0.193	-0.555
2	0.585	-1.320	0.819	-0.163	-0.569
2	0.376	-1.310	0.890	-0.186	-0.557
2	0.403	-1.230	0.785	-0.018	-0.471
3	-0.201	-1.510	0.489	-0.004	-0.466
3	0.590	-1.380	0.739	-0.071	-0.536
3	0.593	-1.380	0.751	-0.082	-0.539
3	0.658	-0.962	0.373	-0.144	-0.665
3	0.520	-1.370	0.890	-0.003	-0.508
3	0.279	-1.550	0.839	-0.186	-0.608
3	-0.062	-1.080	0.662	-0.004	-0.488
3	0.657	-1.310	0.849	-0.085	-0.530
3	-0.090	-1.100	0.788	-0.163	-0.527
3	0.533	-1.490	0.769	0.040	-0.530
4	0.549	-1.290	0.801	-0.188	-0.538
4	0.270	-1.390	0.864	-0.182	-0.633
4	0.241	-1.450	0.882	-0.166	-0.635
4	0.455	-1.470	0.764	-0.005	-0.613
4	-0.119	-1.380	0.636	-0.180	-0.601
4	0.162	-1.460	0.753	-0.179	-0.605
4	0.610	-1.010	0.285	-0.158	-0.690
4	0.394	-1.360	0.826	-0.039	-0.551
4	-0.007	-1.290	0.706	0.034	-0.564
4	0.494	-1.260	0.818	-0.195	-0.556
4	0.999	-1.150	0.673	-0.154	-0.518
4	0.243	-1.310	0.784	-0.140	-0.667

- 77 -

L	PC1	PC2	PC3	PC4	PC6
4	0.102	-1.290	0.656	0.177	-0.501
4	0.176	-1.190	0.687	-0.058	-0.504
4	0.444	-1.430	0.540	-0.059	-0.606
5	0.731	-1.380	0.721	-0.247	-0.437
5	0.004	-1.260	0.744	-0.204	-0.625
5	0.864	-1.330	0.667	-0.177	-0.579
5	-0.023	-1.140	0.653	-0.274	-0.600
5	0.671	-1.540	0.729	0.059	-0.539
5	0.622	-1.400	0.823	-0.079	-0.534
5	0.495	-1.230	0.677	-0.069	-0.513
5	0.759	-1.440	0.780	-0.097	-0.608
5	0.581	-1.450	0.835	-0.080	-0.588
5	0.782	-1.360	0.539	-0.088	-0.662
5	0.242	-1.380	0.812	-0.253	-0.647
5	-0.019	-1.210	0.932	-0.074	-0.532
5	0.194	-1.230	0.990	-0.170	-0.529
5	0.682	-1.160	1.080	-0.110	-0.391
5	0.750	-1.330	0.848	-0.108	-0.485
5	0.274	-1.370	0.748	-0.135	-0.538
5	0.510	-1.360	0.785	-0.090	-0.560
5	0.533	-1.440	0.781	-0.053	-0.590
5	0.468	-1.350	0.903	-0.216	-0.532
5	0.747	-1.160	0.733	0.027	-0.441
5	0.593	-1.450	0.746	0.072	-0.555
5	0.570	-1.230	0.841	-0.065	-0.504
5	0.451	-1.430	0.709	-0.052	-0.607
6	0.499	-1.670	0.458	0.002	-0.634
6	0.015	-1.220	0.779	-0.226	-0.605
6	0.427	-1.310	0.809	-0.164	-0.589
6	0.760	-1.390	0.745	-0.267	-0.633
6	0.262	-1.270	0.734	-0.141	-0.603
6	0.825	-1.540	0.724	-0.006	-0.617
6	0.389	-1.470	0.767	-0.072	-0.623
6	-0.249	-1.250	0.494	-0.049	-0.592
6	0.698	-1.590	0.770	0.038	-0.580
6	0.255	-1.360	0.910	-0.258	-0.648
6	0.178	-1.460	0.854	-0.178	-0.598
6	0.857	-1.340	0.784	-0.122	-0.570
6	0.402	-1.320	0.813	-0.063	-0.534
6	0.677	-1.460	0.632	-0.088	-0.583
6	0.485	-1.190	0.900	-0.112	-0.512
6	0.610	-1.260	0.765	-0.104	-0.553
6	0.271	-1.440	0.752	-0.104	-0.621
6	0.498	-1.390	0.801	-0.156	-0.573

- 78 -

L	PC1	PC2	PC3	PC4	PC6
6	0.405	-1.380	0.790	0.034	-0.527
6	0.165	-1.830	0.499	-0.127	-0.531
6	0.582	-1.320	0.755	-0.166	-0.580
6	0.352	-1.410	0.689	-0.041	-0.538
6	0.413	-1.340	0.805	-0.068	-0.574
6	0.065	-1.510	0.689	0.089	-0.554
6	0.364	-1.240	0.845	-0.212	-0.586
6	0.261	-1.440	0.720	0.055	-0.573
6	0.538	-1.270	0.802	-0.074	-0.507
6	0.526	-1.580	0.615	-0.049	-0.606
6	0.397	-1.150	0.778	0.019	-0.473
6	0.292	-1.310	0.758	0.000	-0.584
6	0.433	-1.370	0.797	-0.322	-0.716
6	0.635	-1.190	0.803	-0.116	-0.483
6	-0.064	-1.230	0.813	-0.203	-0.636
6	0.254	-1.530	0.733	-0.091	-0.587
6	0.037	-1.230	0.671	-0.260	-0.454

Principal Components of Reduced-Parameter Constituent Algorithm 2 which differentiates SILs from Normal Columnar Tissues. Results reported for calibration set:

L	PC1	PC2	PC5
1	0.118	0.022	0.021
1	0.238	0.021	-0.035
1	0.190	-0.095	0.056
1	0.275	-0.114	0.013
1	0.195	-0.053	0.002
1	-0.127	0.084	0.008
1	0.222	0.044	0.000
1	0.003	0.056	-0.018
1	-0.429	0.065	0.027
1	0.088	0.007	-0.042
1	0.146	0.031	0.032
1	-0.017	-0.012	-0.005
1	0.174	-0.022	-0.028
1	-0.542	0.127	0.036
1	-0.044	0.029	0.007
1	0.249	-0.052	-0.006
1	0.007	-0.005	-0.016
1	0.079	-0.046	-0.015
1	0.267	0.051	0.074
1	0.247	-0.009	0.039
1	0.248	-0.052	-0.085
1	0.083	0.050	-0.048
1	0.340	-0.073	0.011
1	0.342	0.089	0.057
1	0.463	0.124	0.095
1	0.166	-0.026	0.027
1	-0.170	0.089	0.018
1	0.155	-0.058	-0.047
1	0.079	0.084	-0.009
1	-0.370	-0.067	0.062
1	0.272	0.012	-0.021
1	0.110	0.177	0.131
1	0.060	0.062	-0.019
1	0.280	0.087	0.026
1	0.268	-0.086	-0.002
1	0.239	-0.068	-0.024
1	0.151	-0.084	-0.042
1	0.186	-0.063	-0.034
1	-0.004	-0.200	0.026
1	0.353	0.058	0.026
1	0.087	-0.044	0.019

- 80 -

L	PC1	PC2	PC5
1	0.179	-0.028	0.005
1	0.092	0.130	-0.046
1	0.390	0.011	0.028
1	0.334	0.147	0.086
1	-0.201	-0.065	0.108
1	0.098	0.024	-0.007
1	0.249	-0.036	-0.036
1	0.123	0.008	-0.024
1	0.425	0.087	-0.039
1	0.277	-0.047	0.043
1	0.172	0.061	0.032
1	0.237	-0.106	-0.018
1	0.077	-0.071	-0.037
1	0.396	0.027	-0.057
1	0.146	-0.042	-0.037
1	0.025	-0.034	-0.002
1	0.029	0.016	0.025
1	0.239	-0.038	-0.004
1	0.449	-0.020	-0.026
1	0.243	0.026	-0.016
1	0.187	0.024	-0.015
1	0.243	0.002	-0.015
1	0.261	-0.106	-0.007
1	0.149	0.042	-0.006
1	0.209	0.071	0.000
1	0.363	0.059	0.063
1	0.346	-0.066	0.022
1	0.257	0.043	0.004
1	0.013	-0.115	0.011
1	0.092	-0.062	0.014
1	0.184	0.042	-0.029
1	-0.373	0.015	-0.060
1	0.164	-0.035	-0.018
1	0.207	0.125	0.111
1	0.114	0.006	-0.034
1	0.081	-0.019	-0.004
1	0.284	0.057	0.120
1	0.240	0.125	0.079
1	0.175	0.140	0.039
1	0.086	-0.106	0.021
1	0.171	-0.018	0.027
1	-0.129	0.000	-0.033
1	-0.405	0.057	0.038
1	0.116	0.117	-0.099

L	PC1	PC2	PC5
1	0.046	-0.147	-0.003
1	0.064	-0.058	0.068
1	0.081	-0.045	-0.014
1	0.025	0.025	-0.059
1	0.015	-0.203	0.040
1	0.158	0.074	-0.079
1	0.229	0.079	0.011
1	0.146	0.032	-0.029
1	-0.110	0.113	-0.017
2	-0.243	0.099	-0.029
2	-0.111	0.109	0.025
2	-0.304	0.052	0.062
2	-0.388	-0.008	0.038
2	-0.134	0.168	0.031
2	-0.044	0.049	-0.038
2	-0.412	0.076	0.010
2	-0.389	0.069	0.008
2	-0.242	0.152	-0.002
2	-0.258	0.059	0.013
2	-0.074	-0.025	0.009
2	-0.388	0.079	0.004
2	-0.248	-0.046	-0.042
3	-0.231	-0.054	0.051
3	-0.099	0.063	0.031
3	-0.026	-0.027	-0.041
3	-0.007	-0.058	-0.025
3	0.013	-0.095	0.008
3	-0.297	-0.118	0.056
3	-0.660	0.204	0.066
3	0.003	0.065	-0.010
3	-0.696	0.166	0.012
3	-0.027	-0.141	0.058
4	-0.108	0.129	-0.005
4	-0.021	-0.098	0.026
4	-0.376	-0.046	-0.024
4	-0.176	-0.140	0.012
4	-0.517	-0.055	0.028
4	-0.241	-0.087	-0.031
4	-0.057	-0.129	-0.003
4	-0.158	-0.096	0.019
4	-0.260	-0.036	-0.052
4	0.031	0.075	-0.007
4	0.224	-0.024	0.027
4	-0.187	0.032	0.049

L	PC1	PC2	PC5
4	-0.356	-0.083	-0.054
4	0.131	0.052	-0.016
4	-0.260	-0.123	0.010
5	0.071	0.037	-0.041
5	-0.311	0.000	0.043
5	0.086	0.008	0.030
5	-0.536	0.088	0.012
5	-0.223	-0.170	-0.050
5	-0.126	0.049	-0.037
5	-0.031	-0.035	-0.072
5	0.098	-0.098	0.074
5	-0.042	-0.110	0.013
5	-0.068	-0.098	0.127
5	-0.178	0.116	0.065
5	-0.439	0.122	-0.028
5	-0.224	0.156	0.001
5	-0.106	0.111	-0.024
5	-0.115	0.111	-0.033
5	-0.002	-0.006	-0.061
5	-0.107	0.033	0.003
5	0.094	-0.065	0.033
5	-0.038	0.052	-0.144
5	0.300	0.072	-0.012
5	-0.122	-0.060	-0.001
5	0.092	-0.012	-0.002
5	-0.145	-0.052	0.026
6	-0.157	-0.274	-0.011
6	-0.295	0.073	-0.065
6	-0.173	0.017	0.006
6	-0.021	-0.002	0.017
6	-0.157	-0.009	0.046
6	-0.066	-0.166	-0.028
6	-0.165	-0.151	0.059
6	-0.581	0.115	0.014
6	-0.190	-0.212	-0.011
6	-0.226	-0.014	0.047
6	-0.259	-0.011	0.013
6	0.092	-0.019	0.013
6	-0.079	-0.032	-0.007
6	0.112	-0.015	0.036
6	-0.116	0.187	-0.076
6	0.117	0.048	-0.009
6	-0.028	-0.079	0.007
6	0.075	0.072	0.009

- 83 -

L	PC1	PC2	PC5
6	-0.197	-0.081	0.022
6	-0.477	-0.439	-0.113
6	0.097	-0.037	-0.012
6	-0.157	-0.019	-0.019
6	-0.133	-0.010	0.015
6	-0.525	-0.174	-0.121
6	0.025	-0.008	0.011
6	-0.100	-0.314	0.069
6	-0.003	0.034	-0.007
6	0.137	-0.049	-0.018
6	-0.024	0.142	-0.038
6	-0.143	-0.011	-0.045
6	-0.232	0.011	-0.195
6	-0.007	0.023	-0.085
6	-0.110	0.073	0.136
6	-0.137	0.049	0.018
6	0.035	-0.101	-0.044

Principal Components of Reduced-Parameter Constituent Algorithm 3 which differentiates HG SILs from LG SILs. Results reported for calibration set:

L	PC1	PC3	PC4	PC7	PC8
1	0.748	0.432	-0.128	-0.304	0.052
1	0.747	0.432	-0.128	-0.281	0.032
1	0.857	0.644	-0.281	-0.223	-0.014
1	0.937	0.678	-0.111	-0.172	0.008
1	0.513	0.791	-0.172	-0.254	0.075
1	0.150	0.803	-0.165	-0.271	0.013
1	0.828	0.772	-0.179	-0.232	0.077
1	0.768	0.870	-0.187	-0.229	0.074
1	0.334	0.819	-0.183	-0.214	0.086
1	0.929	0.657	-0.183	-0.175	0.017
1	0.989	0.676	-0.143	-0.192	0.039
1	0.584	0.789	-0.170	-0.191	0.032
1	0.807	0.716	-0.165	-0.186	0.061
1	-0.221	0.509	-0.117	-0.193	0.006
1	0.729	0.699	-0.146	-0.164	-0.011
1	0.969	0.646	-0.158	-0.243	0.051
1	0.701	0.734	-0.056	-0.198	0.045
1	0.773	0.722	-0.071	-0.173	0.048
1	0.878	0.697	-0.173	-0.207	0.061
1	0.766	0.535	-0.141	-0.252	0.031
1	0.645	0.690	-0.125	-0.159	0.030
1	0.741	0.386	-0.060	-0.187	0.026
1	0.972	0.761	-0.146	-0.177	0.032
1	0.680	0.774	-0.179	-0.173	-0.008
1	0.993	0.718	-0.213	-0.176	0.021
1	0.848	0.819	-0.130	-0.191	0.019
1	0.316	0.794	-0.125	-0.281	0.117
1	0.579	0.730	-0.077	-0.253	0.043
1	0.738	0.851	-0.083	-0.222	0.022
1	0.303	0.816	0.046	-0.252	0.020
1	0.862	0.736	-0.124	-0.213	0.054
1	0.975	0.635	-0.116	-0.166	0.056
1	0.935	0.763	-0.065	-0.199	0.032
1	0.897	0.703	-0.111	-0.214	0.063
1	0.697	0.821	-0.085	-0.210	0.052
1	0.789	0.724	-0.075	-0.205	0.049
1	0.701	0.700	-0.073	-0.166	0.025
1	0.676	0.765	-0.110	-0.149	0.018
1	0.433	0.666	0.109	-0.136	0.032
1	0.910	0.776	-0.315	-0.154	0.016
1	0.557	0.781	-0.099	-0.220	0.041

- 85 -

L	PC1	PC3	PC4	PC7	PC8
1	0.923	0.873	-0.105	-0.146	0.044
1	0.628	0.845	-0.101	-0.248	0.048
1	1.060	0.705	-0.141	-0.167	0.050
1	0.897	0.598	-0.167	-0.198	0.053
1	0.143	0.845	-0.269	-0.243	0.063
1	0.635	0.807	-0.185	-0.218	0.032
1	0.867	0.763	-0.069	-0.180	0.047
1	0.771	0.769	-0.051	-0.227	0.054
1	0.763	0.681	-0.114	-0.185	0.040
1	1.060	0.697	-0.135	-0.152	0.042
1	1.040	0.754	-0.143	-0.162	0.049
1	0.898	0.724	-0.096	-0.164	0.022
1	0.558	0.789	-0.059	-0.246	0.035
1	0.668	0.771	-0.192	-0.236	0.012
1	0.582	0.713	0.020	-0.188	0.026
1	0.771	0.656	-0.164	-0.163	0.065
1	0.635	0.691	-0.059	-0.154	0.021
1	0.854	0.686	-0.126	-0.151	0.025
1	0.876	0.640	-0.142	-0.171	0.003
1	0.679	0.784	0.006	-0.245	0.046
1	0.690	0.834	-0.146	-0.232	0.035
1	0.711	0.753	-0.096	-0.184	0.067
1	0.694	0.677	-0.099	-0.267	0.044
1	0.812	0.545	-0.188	-0.228	0.083
1	0.671	0.754	-0.054	-0.210	0.059
1	0.869	0.844	-0.337	-0.190	0.049
1	1.000	0.724	-0.160	-0.220	0.042
1	0.860	0.693	-0.166	-0.203	0.027
1	0.476	0.738	-0.152	-0.252	0.040
1	0.804	0.728	-0.141	-0.229	0.005
1	0.729	0.790	-0.069	-0.184	0.056
1	0.167	0.671	-0.096	-0.196	0.078
1	0.929	0.733	-0.087	-0.182	0.015
1	0.933	0.651	-0.113	-0.140	0.035
1	0.581	0.710	-0.182	-0.189	0.026
1	0.655	0.765	-0.077	-0.175	0.022
1	0.921	0.652	-0.187	-0.134	0.057
1	0.753	0.620	-0.111	-0.150	0.059
1	0.730	0.687	-0.124	-0.156	0.047
1	0.615	0.692	-0.014	-0.194	0.086
1	0.640	0.655	-0.012	-0.197	0.053
1	0.155	0.583	-0.225	-0.285	0.020
1	-0.120	0.592	-0.191	-0.257	0.052
1	0.694	0.727	-0.123	-0.111	0.012

L	PC1	PC3	PC4	PC7	PC8
1	0.556	0.645	-0.043	-0.189	0.026
1	-0.245	0.594	-0.170	-0.183	0.030
1	0.126	0.639	-0.083	-0.304	0.065
1	0.726	0.668	-0.131	-0.153	0.055
1	0.633	0.669	-0.076	-0.202	0.052
1	0.879	0.732	-0.224	-0.150	0.048
1	0.898	0.606	-0.183	-0.163	0.012
1	0.641	0.788	-0.113	-0.198	0.044
1	-0.132	0.564	-0.168	-0.220	0.026
2	0.407	0.803	-0.116	-0.236	0.019
2	0.494	0.841	-0.228	-0.215	0.088
2	0.474	0.762	-0.273	-0.165	-0.025
2	0.009	0.734	-0.455	-0.235	0.006
2	0.254	0.903	-0.364	-0.250	0.029
2	0.496	0.868	-0.143	-0.251	0.048
2	-0.170	0.642	0.053	-0.182	0.033
2	0.179	0.977	-0.370	-0.191	0.081
2	0.490	0.905	-0.200	-0.187	0.089
2	0.383	0.739	-0.193	-0.216	0.066
2	0.585	0.819	-0.163	-0.209	0.060
2	0.376	0.890	-0.186	-0.235	0.030
2	0.403	0.785	-0.018	-0.141	0.036
3	-0.201	0.489	-0.004	-0.120	0.018
3	0.590	0.739	-0.071	-0.266	0.060
3	0.593	0.751	-0.082	-0.214	0.036
3	0.658	0.373	-0.144	-0.215	0.064
3	0.520	0.890	-0.003	-0.197	0.075
3	0.279	0.839	-0.186	-0.219	0.000
3	-0.062	0.662	-0.004	-0.218	-0.037
3	0.657	0.849	-0.085	-0.260	0.031
3	-0.090	0.788	-0.163	-0.164	-0.063
3	0.533	0.769	0.040	-0.221	0.048
4	0.549	0.801	-0.188	-0.269	0.003
4	0.270	0.864	-0.182	-0.217	-0.049
4	0.241	0.882	-0.166	-0.156	0.065
4	0.455	0.764	-0.005	-0.233	0.054
4	-0.119	0.636	-0.180	-0.140	0.016
4	0.162	0.753	-0.179	-0.159	0.040
4	0.610	0.285	-0.158	-0.228	0.068
4	0.394	0.826	-0.039	-0.232	0.028
4	-0.007	0.706	0.034	-0.163	0.062
4	0.494	0.818	-0.195	-0.259	0.031
4	0.999	0.673	-0.154	-0.135	0.046
4	0.243	0.784	-0.140	-0.259	0.081

L	PC1	PC3	PC4	PC7	PC8
4	0.102	0.656	0.177	-0.171	0.064
4	0.176	0.687	-0.058	-0.244	0.054
4	0.444	0.540	-0.059	-0.266	-0.008
5	0.731	0.721	-0.247	-0.203	0.018
5	0.004	0.744	-0.204	-0.144	0.012
5	0.864	0.667	-0.177	-0.183	0.050
5	-0.023	0.653	-0.274	-0.144	-0.129
5	0.671	0.729	0.059	-0.158	0.048
5	0.622	0.823	-0.079	-0.172	0.052
5	0.495	0.677	-0.069	-0.142	0.045
5	0.759	0.780	-0.097	-0.250	0.025
5	0.581	0.835	-0.080	-0.207	0.035
5	0.782	0.539	-0.088	-0.211	0.007
5	0.242	0.812	-0.253	-0.244	0.067
5	-0.019	0.932	-0.074	-0.118	-0.131
5	0.194	0.990	-0.170	-0.168	-0.026
5	0.682	1.080	-0.110	-0.099	0.095
5	0.750	0.848	-0.108	-0.183	0.016
5	0.274	0.748	-0.135	-0.177	-0.021
5	0.510	0.785	-0.090	-0.151	0.033
5	0.533	0.781	-0.053	-0.257	0.069
5	0.468	0.903	-0.216	-0.185	0.049
5	0.747	0.733	0.027	-0.273	0.027
5	0.593	0.746	0.072	-0.242	0.035
5	0.570	0.841	-0.065	-0.162	0.041
5	0.451	0.709	-0.052	-0.199	0.006
6	0.499	0.458	-0.002	-0.240	0.081
6	0.015	0.779	-0.226	-0.126	0.069
6	0.427	0.809	-0.164	-0.204	0.055
6	0.760	0.745	-0.267	-0.175	0.051
6	0.262	0.734	-0.141	-0.294	-0.078
6	0.825	0.724	-0.006	-0.153	0.040
6	0.389	0.767	-0.072	-0.268	0.073
6	-0.249	0.494	-0.049	-0.104	0.052
6	0.698	0.770	0.038	-0.118	0.030
6	0.255	0.910	-0.258	-0.261	0.024
6	0.178	0.854	-0.178	-0.207	0.024
6	0.857	0.784	-0.122	-0.242	0.050
6	0.402	0.813	-0.063	-0.157	0.043
6	0.677	0.632	-0.088	-0.153	0.052
6	0.485	0.900	-0.112	-0.182	0.083
6	0.610	0.765	-0.104	-0.241	0.046
6	0.271	0.752	-0.104	-0.250	0.024
6	0.498	0.801	-0.156	-0.235	0.047

- 88 -

L	PC1	PC3	PC4	PC7	PC8
6	0.405	0.790	0.034	-0.223	0.055
6	0.165	0.499	-0.127	-0.037	0.107
6	0.582	0.755	-0.166	-0.159	0.039
6	0.352	0.689	-0.041	-0.145	0.039
6	0.413	0.805	-0.068	-0.245	0.067
6	0.065	0.689	0.089	-0.153	0.038
6	0.364	0.845	-0.212	-0.256	0.079
6	0.261	0.720	0.055	-0.232	0.054
6	0.538	0.802	-0.074	-0.253	0.071
6	0.526	0.615	-0.049	-0.174	0.050
6	0.397	0.778	0.019	-0.201	0.059
6	0.292	0.758	0.000	-0.217	0.052
6	0.433	0.797	-0.322	-0.248	0.037
6	0.635	0.803	-0.116	-0.195	0.064
6	-0.064	0.813	-0.203	-0.183	-0.045
6	0.254	0.733	-0.091	-0.194	0.050
6	0.037	0.671	-0.260	-0.106	0.115

VI. References

The following references, to the extent that they provide exemplary experimental details or other information supplementary to that set forth herein, are incorporated by
5 reference:

1. Wright T.C., Kurman R.J., Ferenczy A. (1994) Cervical Intraepithelial Neoplasia. In *Pathology of the Female Genital Tract*. (Edited by A.Blaustein), New York.
2. American Cancer Society (1995) Cancer Facts and Figures, 12.
- 10 3. Kurman R.J., Henson D.E., Herbst A.L., Noller K.L., Schiffman M.H. (1994) Interim guidelines of management of abnormal cervical cytology. *JAMA* 271, 1866-1869.
4. World Health Organization, Geneva (1988) Cytological Screening in the Control of Cervical Cancer: Technical Guidelines.
5. Fahey M.T., Irwig L., Macaskill P. (1995) Meta-analysis of Pap test accuracy.
15 *American J Epidemiology* 141(7), 680-689.
6. Wilkinson E.J. (1990) Pap Smears and screening for cervical neoplasia. *Clin Obstet Gynecol* 33, 817-825.
7. Koss L.G. (1989) The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. *JAMA*, 737-743.
- 20 8. Burke L., Ducatman B.S. (1991) Colposcopy, text and atlas. Appleton and Large, Norwalk, CT.
9. Mitchell MF. (1994) Accuracy of Colposcopy. *Consultations in Obstetrics and Gynecology* 6(1), 70-73.
- 25 10. Richards-Kortum R.R., Rava R.P., Fitzmaurice M., Sivak M.V. (1991) Spectroscopic diagnosis of colonic dysplasia. *Photochemistry and Photobiology* 53, 777-786.

11. Kapadia C.R., Cutruzzola F.W., O'Brien K.M., Stetz M.L., Enriquez R., Deckelbaum L.I. (1990) Laser-induced fluorescence spectroscopy of human colonic mucosa, *Gastroenterology* 99, 150-157.
- 5 12. Marchesini R., Brambilla M., Pignoli E., Bottioli G., Croce A.C., Dal Fante M., Spinelli P., Di Palma S. (1992) Light-induced fluorescence spectroscopy of adenomas, adenocarcinomas and non-neoplastic mucosa in human colon, *J Photochemistry and Photobiology* 14(3), 219-30.
- 10 13. Cothren R.M., Richards-Kortum R.R., Rava R.P., Boyce G.A., Doxtader M., Blackman R., Ivanc T., Hayes G.B., Feld M.S., Petras R.E. (1990) Gastrointestinal tissue diagnosis by laser induced fluorescence spectroscopy at endoscopy. *Gastrointestinal Endoscopy* 36, 105-111.
14. Schomacker K.T., Frisoli J.K., Compton C.C., Flotte T.J., Richter J.M., Nishioka N.S., Deutsch T.F. (1992) Ultraviolet laser induced fluorescence of colonic tissue: basic biology and diagnostic potential. *Lasers in Surgery and Medicine* 12, 63-78.
- 15 15. Hung J., Lam S., LeRiche J.C., Palcic B. (1991) Autofluorescence of normal and malignant bronchial tissue. *Lasers in Surgery and Medicine* 11(2), 99-105.
16. Lam S., Hung J.Y.C., Kennedy S.M., Leriche J.C., Vedal R., Nelems B., Macaulay C.E., Palcic B. (1992) Detection of dysplasia and carcinoma in situ by ratio fluorimetry. *Am Rev Dis* 146, 1458-1461.
- 20 17. Lam S., Macaulay C., Palcic B. (1993) Detection and localization of early lung cancer by imaging techniques. *Chest* 103, 12s-14s.
18. Yuanlong Y., Yanming Y., Fuming L., Yufen L., Paozhong M. (1987) Characteristic autofluorescence for cancer diagnosis and its origin, *Lasers in Surgery and Medicine* 7, 528-532.
- 25 19. Montan S., Stromblad L.G. (1987) Spectral characterization of brain tumors utilizing laser-induced fluorescence. *Lasers in Life Sciences* 1(4), 275-285.

20. Liu C.H., Das B.B., Sha Glassman W.L., Tang G.C., Yoo K.M., Zhu H.R., Akins D.L., Lubicz S.S., Cleary J., Prudente R. (1992) Raman, fluorescence and time-resolved light scattering as optical diagnostic techniques to separate diseased and normal biomedical media. *J Photochemistry and Photobiology* 16(2), 187-209.
- 5 21. Glassman W.S. Liu C.H., Tang G.C., Lubicz S., Alfano R.R. (1992) Ultraviolet excited fluorescence spectra from non-malignant and malignant tissues of the gynecologic tract. *Lasers in Life Sciences* 5, 49-58.
22. Lohmann W., Mußmann J., Lohmann C., Kunzel W. (1989) Fluorescence of the cervix uteri as a marker for dysplasia and invasive carcinoma. *European Journal of*
- 10 *Obstetrics and Gynecology and Reproductive Biology* 131, 249-253.
23. Mahadevan A., Mitchell M., Silva E., Thomsen S., Richards-Kortum R.R. (1993) Study of the fluorescence properties of normal and neoplastic human cervical tissue. *Lasers in Surgery and Medicine* 13, 647-655.
24. Braichotte D.R., Wagnieres G.A., Bays R., Monnier P., Van den Bergh H.E. (1995)
- 15 *Clinical pharmacokinetic studies of photofrin by fluorescence spectroscopy in the oral cavity, the esophagus and the bronchi. Cancer* 75(11), 2768-78.
25. Gray M.J., Lipson R., Maeck J.V.S., Parker L., Romeyn D. (1967) Use of hematoporphyrin derivative in detection and management of cervical cancer. *Am J Obst & Gynec*, 766-770.
- 20 26. Kennedy J.C. Pottier R.H. (1992) Endogenous protoporphyrin IX, a clinical useful photosensitizer for photodynamic therapy. *J Photochem Photobiol B: Biol* 14, 275-292.
27. Loh C.S., MacRobert A.J., Bedwell J., Regula J., Krasner N., Bown S.G. (1993) Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. *British Journal of Cancer* 68(1), 41-51.
- 25 28. Dillon R.W., Goldstein M. (1984) *Multivariate Analysis: Methods and Applications*. John Wiley and Sons, New York.

29. Walpole R.E., Myers R.H. (1987) *Probability and Statistics for Engineers and Scientists*. Decker, New York.
30. Albert A., Harris E.K. (1987) *Multivariate Interpretation of Clinical Laboratory Data*. Marcel Dekker, New York.
- 5 31. Devore J.L. (1992) *Probability and Statistics for Engineering and the Science*. Brooks/Cole, Pacific Grove.

- 93 -

CLAIMS

1. A method of detecting tissue abnormality in a tissue sample comprising the steps of:
- 5
- (i) providing a tissue sample;
 - (ii) illuminating said sample with electromagnetic radiation wavelengths of about 337 nm, about 380 nm and about 460 nm to produce three fluorescence intensity spectra;
 - 10 (iii) detecting a plurality of emission wavelengths from said fluorescence intensity spectra; and
 - (iv) calculating from said emission wavelengths a probability that said sample is abnormal.
- 15
2. The method of claim 1, wherein the illumination wavelengths are in the ranges of 317-357 nm, 360-400 nm and 440-480 nm.
3. The method of claim 1, further comprising the step of preprocessing data at the emission wavelengths to reduce inter-sample and intra-sample variation.
- 20
4. The method of claim 1, wherein said establishing step comprises normalizing said spectra relative to a maximum intensity within said spectra.
5. The method of claim 1, wherein said establishing step does not comprise mean-scaling said spectra.
- 25
6. The method of claim 1, wherein said emission wavelengths are about 410 nm, about 460 nm, about 510 nm and about 580 nm for an illumination of about 337 nm; about 460 nm, about 510 nm, about 580 nm, about 600 nm and about 640 nm for an illumination of about 380 nm; and about 510, about 580 nm, about 600 nm, about 620 nm, about 640 nm and about 660 nm for an illumination of about 460 nm.
- 30

- 94 -

7. The method of claim 1, wherein said sample is illuminated *in vitro*.

8. The method of claim 1, wherein said sample is illuminated *in vivo*.

5 9. The method of claim 7, wherein said providing step comprises obtaining said tissue sample by biopsy.

10. The method of claim 9, wherein said providing step further comprises generating a monolayer cell touch preparation or a pellet.

10

11. The method of claim 10, wherein said providing step further comprises ethanol fixation of said tissue sample.

15

12. The method of claim 1, wherein said illuminating comprises illuminating said sample substantially normal to a surface of said sample, and wherein said detecting step comprises, detecting said spectra at an angle of approximately 20° from normal.

13. The method of claim 1, wherein said probability distinguishes normal squamous and abnormal tissue.

20

14. The method of claim 1, wherein said probability distinguishes normal columnar epithelium and abnormal tissue.

25

15. The method of claim 1, wherein said probability distinguishes inflamed and abnormal tissue.

16. The method of claim 1, wherein said probability distinguishes low grade SIL and high grade SIL tissue.

30

17. The method of claim 1, wherein said probability distinguishes normal and high grade SIL tissue.

18. A method of developing a model for differentiating between normal and abnormal tissue in a tissue sample, comprising the steps of:

- (i) providing a plurality of tissue samples;
- 5 (ii) illuminating said samples with electromagnetic radiation wavelengths of about 337 nm, about 380 nm and about 460 nm to produce three fluorescence intensity spectra for each of said samples;
- (iii) detecting a plurality of emission wavelengths from said fluorescence intensity spectra;
- 10 (iv) forming a set of principal components from said spectra, said principal components being defined as providing statistically significant differences between normal tissue and various forms of abnormal tissue; and
- (v) subjecting said principal components to logistic discrimination to develop a relevant model.

15

19. The method of claim 18, wherein the illumination wavelengths are in the ranges of 317-357 nm, 360-400 nm and 440-480 nm.

20. A method of detecting tissue abnormality in a tissue sample comprising the steps of:

20

- (i) providing a tissue sample;
- (ii) illuminating said sample with electromagnetic radiation wavelengths of about 337 nm, about 380 nm and about 460 nm to produce three
- 25 fluorescence intensity spectra;
- (iii) detecting a plurality of emission wavelengths from said fluorescence intensity spectra; and
- (iv) establishing from principal components PC1, PC3 and PC7 of step (iii) a probability that said sample is abnormal.

30

- 96 -

21. A method of detecting tissue abnormality in a tissue sample comprising the steps of:

- (i) providing a tissue sample;
- 5 (ii) illuminating said sample with electromagnetic radiation wavelengths of about 337 nm, about 380 nm and about 460 nm to produce three fluorescence intensity spectra;
- (iii) detecting a plurality of emission wavelengths from said fluorescence intensity spectra; and
- 10 (iv) establishing from principal components PC1, PC2, PC4 and PC5 of step (iii) a probability that said sample is abnormal.

22. A method of detecting tissue abnormality in a tissue sample comprising the steps of:

- (i) providing a tissue sample;
- 15 (ii) illuminating said sample with electromagnetic radiation wavelengths of about 337 nm, about 380 nm and about 460 nm to produce three fluorescence intensity spectra;
- 20 (iii) detecting a plurality of emission wavelengths from said fluorescence intensity spectra; and
- (iv) establishing from principal components PC1, PC3 PC6 and PC8 of step (iii) a probability that said sample is abnormal.

23. A method of detecting tissue abnormality in a subject *in vivo* comprising the steps of:

- (i) illuminating a tissue sample *in vivo* with a plurality of electromagnetic radiation wavelengths to produce a plurality of fluorescence intensity spectra;
- 30

- 97 -

- (ii) detecting a plurality of emission wavelengths from said fluorescence intensity spectra; and
- (iii) establishing from said emission wavelengths a probability that said sample is abnormal.

5

24. The method of claim 23, wherein the plurality of illumination wavelengths includes at least three wavelengths having the ranges of 317-357 nm, 360-400 nm and 440-480 nm.

10

25. The method of claim 23, further comprising the step of preprocessing data at the emission wavelengths to reduce inter-patient and intra-patient variation.

26. A method for diagnosing cervical precancer in a patient comprising the steps of:

15

- (i) illuminating cervical tissue of said patient with a plurality of electromagnetic radiation wavelengths to produce a plurality of fluorescence intensity spectra;
- (ii) detecting a plurality of emission frequencies from said fluorescence intensity spectra;
- (iii) calculating from said emission frequencies a probability that said sample is abnormal; and
- (iv) diagnosing said cervical tissue as a function of said calculation.

20

27. The method of claim 1, wherein said method further comprises illuminating said sample with an electromagnetic radiation wavelength in the near infrared sufficient to produce a Raman spectrum and detecting a Raman spectrum therefrom.

25

28. The method of claim 27, wherein the near infrared illumination wavelength is about 789 nm.

30

- 98 -

29. The method of claim 28, wherein said emission frequencies are shifted about 626, 818, 978, 1070, 1175, 1246, 1330, 1454 and 1656 cm^{-1} from said illumination wavelength.

5 30. The method of claim 27, wherein at least one of said emission frequencies is associated with compound selected from the group consisting of collagen, phospholipids and glucose-1-phosphate.

31. An apparatus for detecting tissue abnormality, comprising:

- 10
- (i) a light source for emitting a plurality of electromagnetic radiation wavelengths;
 - (ii) a probe connected to said light source, said probe adapted to apply said plurality of electromagnetic radiation wavelengths to tissue under test and to gather fluorescence emitted from said tissue under test;
 - 15 (iii) detection means, connected to said probe, for detecting at least one fluorescence spectrum emitted from said tissue under test;
 - (iv) a programmed computer connected to said detection means, for processing said at least one fluorescence spectrum according to a predetermined algorithm to establish a probability that said tissue under
 - 20 test is abnormal.

32. The apparatus of claim 31, said light source comprising a nitrogen pumped laser.

25 33. The apparatus of claim 32, said plurality of electromagnetic radiation wavelengths comprising about 337 nm, about 380 nm and about 460 nm.

34. The apparatus of claim 31, further comprising a polychromator connected intermediate said probe and said detection means.

- 99 -

35. The apparatus of claim 31, said probe comprising excitation optical fibers for applying said plurality of electromagnetic wavelength to said tissue under test, collection optical fibers for gathering said fluorescence emitted from said tissue under test, and a shield overlying ends of said excitation optical fibers and said collection optical fibers.

5

36. The apparatus of claim 32, said predetermined algorithm including principal components that predict statistically relevant differences between fluorescence emission wavelengths from normal and abnormal tissues for said plurality of applied electromagnetic radiation wavelengths.

10

37. The apparatus of claim 36, wherein said abnormal tissues are selected from the group consisting of inflamed, low grade SIL and high grade SIL.




FIG. 1

2/11




FIG 2

3/11




FIG. 3

4/11




FIG. 4

5/11




FIG. 5

6/11




FIG. 6

7/11




FIG. 7

8/11




FIG. 8

9/11




FIG. 9

10/11




FIG. 10

11/11




FIG. 11

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/10729

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61B5/00 G01N21/64

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	W0 90 12536 A (MIT) 1 November 1990 see abstract see page 11, line 7 - line 31 see page 13, line 10 - line 18 see page 20, line 15 - line 19 see page 22, line 3 - line 6 see page 22, line 22 - page 23, line 2 see page 28, line 1 - line 7 see page 28, line 19 - line 25 see page 29, line 32 - page 30, line 2 see figures 3,5,7,8,12	1,3,7-9, 23-26, 31-35
Y	see figures 23,24,31-33 --- -/-	18-22, 27,28

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

8 October 1997

Date of mailing of the international search report

17/10/1997

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Thomas, R.M.

INTERNATIONAL SEARCH REPORT

Inte: Jnal Application No

PCT/US 97/10729

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 348 003 A (CARO) 20 September 1994 see column 1, paragraph 1	18-22
A	see column 14, line 3 - line 23 ---	36
Y	US 5 293 872 A (ALFANO) 15 March 1994 see abstract see column 4, line 58 - line 61 ---	27, 28
A	WO 90 06718 A (MIT) 28 June 1990 see abstract see page 2, line 15 - line 31 see page 3, line 31 - page 4, line 13 see page 19, line 17 - line 20 see page 32, line 14-17 see page 41, line 22 - page 44, line 4 see claims 1,4,5,13; figures 3A,3B,22-25 ---	1,2,7, 18-24, 27,30, 33-35
X	WO 94 26168 A (UNIVERSITY OF TEXAS) 24 November 1994 see abstract see page 15, line 4 - line 22 see page 17, line 18 - line 35 see figure 5 ---	26,31
A	WO 96 28084 A (UNIVERSITY OF TEXAS) 19 September 1996 see abstract see page 4, line 25 - page 5, line 4 see page 27, line 27 - line 34 see claims 1-3,5 ---	1,8,14, 15,18, 20-23, 25,26, 31,32, 34,35
P,X	WO 96 30746 A (UNIVERSITY OF TEXAS) 3 October 1996 see abstract see page 6, line 28 - line 33 see page 7, line 12 - line 27 see page 8, line 1 - line 18 see page 9, line 21 - page 10, line 13 ---	1-4,7,8, 13-29, 31-37
P,A		1,3,4,7, 9-11,18, 20-23, 25,36
P,X		26,31

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter national Application No

PCT/US 97/10729

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9012536 A	01-11-90	EP 0466828 A US 5421337 A	22-01-92 06-06-95
US 5348003 A	20-09-94	NONE	
US 5293872 A	15-03-94	NONE	
WO 9006718 A	28-06-90	AT 133545 T DE 68925586 D DE 68925586 T EP 0449883 A US 5562100 A US 5419323 A	15-02-96 14-03-96 24-10-96 09-10-91 08-10-96 30-05-95
WO 9426168 A	24-11-94	US 5421339 A AU 6946894 A CA 2162922 A EP 0702526 A JP 8511179 T US 5623932 A	06-06-95 12-12-94 24-11-94 27-03-96 26-11-96 29-04-97
WO 9628084 A	19-09-96	CA 2190374 A EP 0765134 A	19-09-96 02-04-97
WO 9630746 A	03-10-96	US 5612540 A	18-03-97

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.